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Abstract
Tuominen U. The effect of waiting time on health outcomes and costs of total 
joint replacement in hip and knee patients. A prospective randomized 
controlled trial. Helsinki: The Social Insurance Institution of Finland, Studies in 
social security and health 126, 2013. 114 pp. ISBN 978-951-669-911-3 (print), 
ISBN 978-951-669-912-0 (pdf ). 
Osteoarthritis is the most common cause of musculoskeletal 
disability and pain. Long waiting times for elective surgery have 
been a concern in many countries. The aim of this study was to 
evaluate the effect of waiting time on health outcomes and costs 
of total joint replacement in hip and knee patients. When placed 
on the waiting list, patients were randomly allocated to a short 
waiting time (waiting time ≤ 3 months) or a non-fixed waiting 
time (waiting time not fixed in advance, patients followed the 
hospitals’ routine practice) groups. The outcomes were measured 
by the15D questionnaire, modified Harris Hip and Knee Scores 
and Visual Analogue Scale. The use and costs of medication,
health care and social services were measured. The measurement 
points were, when placed on the waiting list upon admission,
three months and twelve months postoperatively. Quality­
adjusted life years (QALYs) were calculated to evaluate the effect 
of waiting time on the cost-utility of total joint replacement. The 
waiting time difference did not result in a significant difference 
in health outcomes. After surgery, the mean scores of outcomes 
improved in both randomized groups by a statistically significant 
margin. The point estimates from cost-utility analyses showed 
that hip patients in the short waiting time group compared to 
the non-fixed group gained more QALYs at lower costs, thus 
suggesting a strong dominance for the shorter waiting time. In 
knee patients, the situation was the opposite. There were refusals 
and dropouts during the follow-up, which might introduce 
bias and uncertainly into the results. There does not seem to 
be a significant difference between the cost-utility of short and 
longer waiting times for total joint replacement, at least given the 
waiting time difference between our study groups. However, due 
to quite a lot of uncertainty in the results, one has to be cautious 
about generalizing the findings. 
Keywords: total hip replacement, total knee replacement,
osteoarthritis, joint replacement operations, waiting time, health­
related quality of life, health outcomes, costs, cost-utility analysis 
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Tiivistelmä 
Tuominen U. Jonotusajan vaikutukset lonkan ja polven tekonivelleikkaus­
hoidon lopputulokseen ja kustannuksiin. Satunnaistettu kontrolloitu 
tutkimus. Helsinki: Kela, Sosiaali- ja ter veystur van tutkimuksia 126, 2013. 114 s. 
ISBN 978-951-669-911-3 (nid.), ISBN 978-951-669-912-0 (pdf ). 
Nivelrikko on yksi yleisimmistä liikuntakyvyttömyyttä 
ja kipua aiheuttavista tuki- ja liikuntaelinsairauksista.
Tekonivelkirurgiaan liittyvät pitkät jonotusajat ovat olleet 
länsimaissa vuosikymmenien ajan huolen aiheena. Tämän 
tutkimuksen tarkoitus oli selvittää jonotusajan pituuden 
vaikutusta polven ja lonkan primaariin tekonivelleikkaukseen 
liittyviin terveysvaikutuksiin sekä kustannuksiin ennen 
leikkausta ja sen jälkeen. Tekonivelleikkausjonoon asetetut 
polvi- ja lonkkapotilaat satunnaistettiin kahteen ryhmään:
lyhyen jonotusajan ryhmään ja normaalin sairaalakäytännön 
mukaisesti jonottavaan ryhmään. Terveysvaikutuksia mitattiin 
15D-, Harris Hip Score -, Knee Score - ja VAS-mittareilla.
Tietoja kerättiin lääkkeiden sekä sosiaali- ja terveyspalvelujen 
käytöstä ja kustannuksista. Vaikuttavuutta arvioitiin 
kustannusutiliteettianalyysilla. Mittaukset tehtiin jonoon 
asettamisajankohtana, sairaalaan saapumisajankohtana sekä 
kolmen ja kahdentoista kuukauden kuluttua leikkauksesta 
Tulokset perustuvat satunnaistetun aineiston hoitoaikeen 
mukaiseen analyysiin, ja tulokset on testattu herkkyysanalyyseilla.
Jonotusajan pituudella ei ollut satunnaistettujen vertailuryhmien 
välillä merkittävää vaikutusta elämänlaatuun, kipuun eikä 
liikuntakykyyn. Leikkauksen jälkeiset vaikuttavuusarvot olivat 
tilastollisesti merkitsevästi parempia kuin arvot sairaalaan 
saavuttaessa. Kustannusvaikuttavuusanalyysin mukaan 
nopean leikkausryhmän lonkkapotilaat saavuttivat enemmän 
laatupainotettuja lisäelinvuosia pienemmillä kustannuksilla 
kuin normaalin käytännön mukaan jonottaneet potilaat.
Polvipotilailla tilanne oli päinvastainen. Tutkimuksen 
seuranta-aikana tapahtuneen kadon vuoksi analyysin tuloksiin 
liittyy jonkin verran epävarmuutta, joten yleistettävää 
johtopäätöstä jonotusajan vaikutuksesta tekonivelleikkausten 
kustannusutiliteettiin ei voida varmistaa.
Avainsanat: lonkan tekonivelleikkaus, polven tekonivelleikkaus,
nivelrikko, tekonivelleikkaukset, jonotusaika, terveyteen liittyvä 
elämänlaatu, terveysvaikutukset, kustannukset, kustannus­
utiliteettianalyysi 
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Sammandrag 
Tuominen U. Väntetidens inverkan på resultatet och kostnader i samband 
med protesoperationer i höft­ och knäled. En randomiserad, kontrollerad 
undersökning. Helsingfors: FPA, Social tr ygghet och hälsa: Undersökningar 126, 
2013. 114 s. ISBN 978-951-669-911-3 (hf t.), 978-951-669-912-0  (pdf ). 
Artros är en av de vanligaste sjukdomarna i rörelseorganen 
som orsakar rörelseoförmåga och smärta. De långa väntetiderna i 
samband med ledproteskirurgi har i decennier varit en anledning 
till bekymmer i västvärlden. Syftet med denna undersökning 
är att undersöka hur väntetid inverkar på hälsoeffekterna 
i samband med primär protesoperation i höft- och knäled 
samt på kostnaderna före och efter operationen. Knä- och 
höftpatienter som hade placerats i kö för en ledprotesoperation 
randomiserades i två grupper: en grupp med kort väntetid 
och en grupp som köade enligt normal sjukhuspraxis.
Hälsoeffekterna mättes med hjälp av 15D, Harris Hip Score, Knee 
Score och VAS. Uppgifter om användningen av och kostnaderna 
för läkemedel samt social- och hälsotjänster samlades in.
Effektiviteten utvärderades med hjälp av kostnadsutilitetanalys.
Mätningar gjordes när personen placerades i kö, vid ankomsten 
till sjukhuset samt 3 och 12 månader efter operationen.
Resultaten grundar sig på intention to treat-analys av ett 
randomiserat material och har testats med sensitivitetsanalyser.
Väntetidens längd hade ingen signifikant inverkan på livskvalitet,
smärta eller rörelseförmåga mellan de randomiserade 
jämförelsegrupperna. Efter operationen var effektivitetsvärdena 
statistiskt signifikant bättre än vid ankomsten till sjukhuset.
Enligt kostnadseffektivitetsanalysen uppnådde den grupp av 
höftpatienter som hade kort väntetid fler kvalitetsjusterade 
levnadsår med lägre kostnader än de patienter som köade på 
normalt vis. I fråga om knäpatienterna var situationen den 
motsatta. På grund av bortfall under observationsperioden var 
analysens resultat i viss mån osäkra. Således går det inte att göra 
någon generaliserbar slutsats gällande väntetidens inverkan på 
kostnadsutiliteten av ledprotesoperationerna.
Nyckelord: protesoperationer i höftled, protesoperationer 
i knäled, artros, protesoperationer, väntetid, livskvalitet i fråga 
om hälsa, hälsoeffekter, kostnader, kostnadsutilitetanalys 
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1 INTRODUCTION 
In many Western countries, long waiting times for elective surgeries are of concern. 
Major joint replacement is an example of surgery with a high demand and relatively 
long waiting periods for patients (Siciliani and Hurst 2003). The mean waiting time for
elective surgical procedures is more than three months in several countries, and waiting
times can stretch out to years. As the population gets older, the prevalence of slowly 
progressive diseases, such as osteoarthritis in the hip and knee joints, is increasing. 
Advances in surgical technology and anaesthesia have improved the range, safety 
and effectiveness of the surgical procedures. There have been a significant number of 
attempts to estimate both the adverse and positive consequences of waiting. Gener­
ally, the consequences of long waiting times are supposed to be: deterioration in the 
condition for which treatment is waited, loss of utility from the delay, a significant 
joint pain or disability, an increase in the costs of surgery and other treatments and 
health care services pre- and postoperatively. However The waiting time study (Sicili­
ani and Hurst 2003) found little evidence from the medical literature of significant 
deterioration of health or worsening surgical outcomes as a result of waiting for elec­
tive surgery in those countries where waiting times are from three months up to six 
months (Siciliani and Hurst 2003). Furthermore, the conclusions in the systematic 
review of Hoogeboom et al. (2009) were that osteoarthritis (OA) patients waiting less 
than 180 days did not experience deterioration in pain or functioning while waiting 
for total joint replacement (TJR). However, according to a review by Hoogeboom et 
al. (2009), more quality studies are needed. 
Johanna Hirvonen (2007) used data from the same study population as in the pre­
sent study to evaluate the effect of waiting time on health outcomes (HRQoL, pain, 
and physical function) during the waiting time, i.e., from baseline to admission and 
service utilization by the admission. According to Hirvonen (2007), use of health 
and social services was low in both waiting time groups while waiting, and longer 
waiting times did not result in poorer HRQoL at admission. The conclusion was that 
those who waited longer used health and social services for a longer period, and this 
would represent a negative impact of waiting. The present study continues to report 
results from the baseline to the end of the follow-up and include results concerning 
QALYs and costs. 
Patients waiting for TJR have poor quality of life and they have difficulties in function­
ing and daily activities (Derrett et al. 1999; Kelly et al. 2001; Croft et al. 2002; Acker­
man et al. 2005; Hirvonen et al. 2006; McHugh et al. 2008). Furthermore, there is a 
significant improvement in HRQoL and increase in the QALYs gained after surgery, 
and a number of studies have asserted that TJRs in hip and knee patients are cost­
effective (Bourne 1996; Lavernia et al. 1997; Rissanen et al. 1997; March et al. 2002 
Räsänen et al. 2007; Xie et al. 2010). 
14 The effect of waiting time on health outcomes and costs of total joint replacement in hip and knee patients
 
The overall objective of this study was to evaluate the effect of waiting time on health 
outcomes and costs of total joint replacement in hip and knee patients. Furthermore, 
the theoretical frame of access to care and the phenomenon of waiting time are
discussed and some examples of actions to reduce waiting times in those countries 
where waiting times to TJR have been of concern (e.g. England, Sweden and Finland) 
are presented. 
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2 OSTEOARTHRITIS 
2.1 Prevalence of osteoarthritis (OA) 
Osteoarthritis is the most common cause of musculoskeletal disability and pain in 
the world. Incidence and prevalence will increase in the coming years due to the 
ageing of the population. The rapid increase in persons 55 years of age and older in 
Western countries implies that OA is becoming a major public health care problem 
(van Es et al. 2011). 
Osteoarthritis is the most common joint disease in the world. Worldwide estimates 
are that 10% of men and 18% of women over 60 years old have symptomatic OA. 
One-third of people over 65 years old have knee OA that can be seen on X-ray. 70% of 
people over 70 years old have x-ray evidence of OA. Before the age of 50, OA is more 
prevalent among men than women. However after the age of 50, women are more 
likely to be affected by OA than men (OECD 2011). 
In Finland, about 400,000 people are affected by OA. Furthermore, 5.7% of males and
4.6% of females over the age of 30 suffer from clinically diagnosed hip OA, and the 
prevalence of clinical knee OA is 6.1% in men and 8.0% in women. The incidence of 
radiological and clinically diagnosed knee and hip OA increases with age both in men
and women. In hip patients, the corresponding OA rates in the earlier Mini-Finland 
Health Survey (Heliövaara et al. 1993) were 4.6% and 5.5% for males and females, 
respectively, i.e., there has been hardly any change in its prevalence since 1990. In 
men under 75 years of age, the prevalence of hip osteoarthritis has remained pretty 
much unchanged, and in older women, the prevalence of hip osteoarthritis has either 
remained unchanged or has marginally increased (Aromaa and Koskinen 2004). In 
knee patients, the corresponding rates in the Mini-Finland Health Survey (Heliövaara
et al. 1993) were 5.5% and 14.5% for males and females, respectively. Among women, 
the prevalence of knee osteoarthritis has thus dropped by more than one-half, which 
is mainly attributable to changes in the age groups under 75 years (Table 1) (Aromaa 
and Koskinen 2004). 
Table 1. Prevalence (%) of hip and knee osteoarthritis according to the examining physician’s diagnosis in Finland 
2000. 
Age 30–44 45–54 55–64 65–74 75–84 85+ 
Hip OA
   Men 0.5 1.8 5.2 12.1 20.3 41.8
   Women 0.4 0.7 3.1 11.6 20.0 24.6 
Knee OA
   Men 0.3 2.6 9.2 10.6 16.3 45.8
   Women 0.4 2.2 8.1 18.4 31.3 35.3 
Source: Aromaa and Koskinen: Health 2000. Health E xamination Sur vey. 
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2.2 Diagnosis of OA 
There are no simple and generally acceptable diagnostic criteria for hip (M16) and knee
(M17) osteoarthritis (ICD10 classification 1994). According to the American College of
R heumatolog y’s (American College of R heumatolog y 2012) clinical/radiological sets
of criteria, the diagnosis of OA is based on the symptoms described by the patient and 
the clinical and radiological findings. Diagnosis is made by reasonable certainty based
on a patient’s history, clinical examination and x-ray (Zhang et al. 2009 and 2010b). 
OA is a common disorder of synovial joints characterized by cartilage degeneration 
with secondary changes in an adjacent bone. It is a common response to a variety of 
metabolic, anatomical and physiological conditions (Atkinson 1984). Primar y OA is
a chronic degenerative disorder related to aging but not caused by it. Osteoarthritis 
is a disease affecting the entire joint, but its aetiology remains mostly unknown.
A characteristic feature of OA is the destruction and later decay of the articular carti­
lage. These changes appear in a radiograph as narrowing of the intra-articular space. 
Articular changes generally proceed slowly over the years, and the damaged cartilage 
does not regenerate. Radiological changes in OA are not always associated with pain 
(Current Care Guidelines 2007). 
The most important risk factors for knee and hip OA are obesity, joint injuries and 
excessive physical stress. Karlson et al. (2003) studied the relation of potential risk 
factors leading to hip replacements. According to this study, higher body mass index 
(BMI > 30) was associated with an increased risk of OA. Because OA is most com­
mon in old people, it is often proposed that the disease is part of the aging process. 
Age had a positive association: women ≥ 70 years of age were nine times more likely 
to have OA than those under 55 years old (Karlson et al. 2003). 
2.3 Treatments of OA 
The aim of treatment for OA is to improve functioning and reduce pain. In its early 
stages, OA is treated with non-surgical measures. Lifestyle modification, such as weight
loss and exercise, support devices, and analgesics are the mainstay of first-line treat­
ment. Simple weight loss can reduce stress on weight-bearing joints and can result in 
reduced pain and increased function (Jordan et al. 2003; Zhang et al. 2005) 
2.3.1 Medication 
Because OA is the most common and slowly progressive disease among the elderly 
population, disease-specific medication has a very important role in first-line phar­
macological treatment. The purpose of medication is to relieve symptoms. The most 
common first-line medication is paracetamol (N02BE01). It is effective as or some­
what less effective than non-steroidal anti-inflammatory drugs (NSAIDs) or COX-2 
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selective NSAIDs in reducing OA pain (Zhang et al. 2010a). Paracetamol is recom­
mended as a first-line drug, and NSAIDs are only recommended as add-on therapy, 
if there is insufficient pain relief (Flood 2010). If the analgesic effects of paracetamol 
and NSAIDs are not sufficient or if they cannot be used due to adverse effects, OA 
pain can be treated with opioids (Avouac et al. 2007). The goal of medication is to 
reduce the symptoms, namely joint pain, stiffness, and swelling. Drugs are also used 
postoperatively as pain killers. 
During the present study, in 2004 the Finnish Social Insurance Institution paid
drug reimbursements for anti-inflammatory and anti-rheumatic products (M01A) 
to 880,700 patients; and in 2006, the reimbursement was paid to 1.2 million patients 
(Finnish statistics on medicine 2006). 
The consumption of anti-inflammatory and anti-rheumatic products (M01A) was 
lower in 2006 (68.3 DDD/1,000 inhabitants/day, a decrease of 11%) than in 2005. Their
cost decreased even more than their consumption from year 2005 to 2006 (24%) (Ta­
ble 2). Until 2010, the consumption of anti-inflammatory and anti-rheumatic products
(M01A) has increased to 83.3 DDD/1,000 inhabitants per day (Finnish statistics on 
medicine 2010).
Table 2. Costs and consumption of M01Aa and one over-the-counter medicine (N02BE01b) in 2004–2006. 
Year 
Consumption of M01Aa 
DDDc/1,000inh/day Costs/1,000 € 
Consumption of N02BE01b 
DDDc/1000inh /day Costs/1,000 € 
2004 74.75 61,833 3.64 13,217 
2005 76.66 56,139 4.62 16,459 
2006 68.34 42,584 3.05 11,306 
a M01A: Anti-inflammator y and anti-rheumatic products, non-steroids.
 
b N02BE01: Paracetamol.
 
c DDD: Defined Daily Dose.
 
Source: Finnish statistics on medicine 2006.
 
2.3.2 Physiotherapy 
The general aims of exercise therapy are to improve functioning, increase levels of 
activity, and to encourage an adequate way of dealing with complaints (van Es et al. 
2011). Appropriate physical exercise represents the basis of OA care before and after 
surgery. Physiotherapy in knee patients has been shown to improve function and 
quality of life, to decrease pain, and delay the need for surgical intervention. Exercise 
by a physical therapist has even been shown to be more effective than medications in 
treating OA of the knee (van Baar et al. 2001). International guidelines recommend 
exercise therapy as part of the treatment. According to a review of The Osteoarthritis 
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Research Society International (OARSI), exercise therapy was shown to reduce pain 
and improve physical functioning in knee patients (van Es et al. 2011). In hip patients, 
guided physical exercises as a treatment may reduce pain and improve functional ca­
pacity. However, there is less available evidence for the effectiveness of exercise therapy
in hip OA than in knee OA (van Es et al. 2011). Postoperative exercise programs are 
essential procedures when recovering after TJR both in hip and knee patients. Exer­
cises aim at quickly regaining motion following the surgery, preventing muscle loss, 
which is inevitable after surgery, rebuilding muscle strength and preventing stiffness 
of the new knee joint. It is important to carefully follow the rehabilitation instructions
given by the physical therapists and doctors (Kuster 2002). 
Of the other physical treatments, cold therapy may reduce knee-joint swelling and 
improve thigh muscle strength, but it has not been shown to have any effect on the 
pain caused by OA of the knee (Adie et al. 2012). Acupuncture treatment appears to 
decrease pain in OA of the knee, at least in the short term, but reliable evidence of 
long-term amelioration of pain and an increase in functional capacity is nevertheless 
lacking (Scharf et al. 2006; Zhang et al. 2010a). 
2 .3 .3 Su r g e r y 
If the conservative treatment options are ineffective, joint replacement surgery may 
be required in advanced cases. Primary total hip replacements (THRs) and total knee 
replacements (TKRs) are surgical procedures to remove the injured part of the joint, 
replacing it with a new artificial part. THRs or TKRs have become standard surgical 
procedures when patients have intractable pain that is unresponsive to conservative 
treatments. 
The volume of TJR in Western countries and Finland 
The number of THRs and TKRs has increased rapidly over the past decade in most 
OECD countries. On average, the rate of THRs increased by over 25 % between 2000 
and 2009. The growth was even higher for TKRs, nearly doubling over the past decade.
There is considerable variation across countries in the rate of hip and knee replace­
ments. Germany, Switzerland and Austria have high rates of both THRs and TKRs. 
The United States and Germany have the highest rate of TKRs, even though the popu­
lation structure of the United States is younger than that of Germany (OECD 2011). 
Annually, over three-quarters of a million surgical total hip and knee replacements 
are carried out in the U.S. (Hoogeboom et al. 2009). In England, the National Annual 
Report summarizes the data and findings for hip and knee procedures carried out in 
England and Wales. The development in 2006 –2010 in primary THR has been from 
58,445 to 77,800, and in TKR from 61,648 to 86,067 surgical procedures (National 
Joint Registry 2011). 
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In Finland, a total of 14,219 primary TJRs were performed in 2004 (7,345 hip and 
6,874 knee ) with the median waiting time for surgery being 181 days (153 days for hip 
replacement and 209 days for knee replacement) (National Research and Development
Centre for Welfare and Health 2006). During the present study from 2005–2006, the 
number of TJRs performed increased (9,316 for hip and 10,411 for knee), and in 2009 
the number of TJRs has decreased once again to the level of 2005. (THL 2011; Figure 1.) 
A total of 18,331 hip and knee replacements were reported to the Finnish Arthroplasty
Register in 2010. According to this register, 7,416 were primary THRs and 9,020 were 
primary TKRs. The total number of operations decreased by 829 in 2009. In 2010, 
TJRs were performed in 60 different hospitals, on average 40% of the operations were 
performed in central hospitals, 30% in district hospitals and 10% in private hospitals.
(THL 2011.) 
A surgical option involving replacement of the hip or knee joint with artificial compo­
nents has been shown to be a highly effective and cost-effective treatment that results 
in improvement in patient functioning and quality of life (Bourne 1996; Rissanen et 
al. 1997; March et al. 2002; Räsänen et al. 2007; Xie et al. 2010). 
Figure 1. The number of total joint replacements in Finland during 1991–2010. 
12,000 
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8,000 
6,000 
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4,000 Primary (K) 
2,000 
0
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1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 
H = hip, K = knee. 
Source: THL 2011. 
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2.4 Co-morbidity and OA 
According to the Finnish Health 2000 Health Examination Survey, over 80% of the 
inhabitants in the age group of 30 to 44 years regarded their health as good or fairly 
good. In comparison, among those close to retirement age (55 to 64 years), about half 
felt their health state at least fairly good. In addition, only one-quarter of persons aged
75 or over said that their health was good or fairly good. Similarly, one-third of the 
responders in the age group of 30 to 44 reported that they suffered from at least one 
chronic illness. In the age group of 65 years and over, the prevalence of at least one 
chronic disease has increased up to 80 –90%. The prevalence of chronic illness was 
about the same among men and women in all age groups (Aromaa and Koskinen 2004). 
Co-morbid or coexisting disease refers to the occurrence of two or more diseases 
in the same individual. Each co-morbid disease may have its own effect on health­
related quality of life (HRQoL) while also having a clinical effect on a patients’ sense 
of well-being. Co-morbidity has an important cofounder effect on HRQoL of patients
waiting for TJR. It is also important for studies of patients with chronic disease, in 
whom mortality is rare and the goal of medical care is to control the course of the 
disease and maximize the quality of life (Xuan et al. 1999). The most common chronic
diseases in Finland are: cardiovascular disease, musculoskeletal disease, diabetes, and
lung diseases (Aromaa and Koskinen 2004). 
Evaluations on how different diseases affect patients’ HRQoL focus mostly on the index
disease, considering the effect of co-morbidity to a lesser extent. However, when the 
focus is on the consequences on the costs of the medical care – co-morbidity becomes 
an important factor. 
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3 LITERATURE REVIEW OF WAITING TIME AND COST­EFFECTIVENESS OF TOTAL JOINT 
REPLACEMENT 
The focus of the literature review was to summarize the findings concerning the 
effect of waiting time on HRQoL and other health outcomes and the costs of total 
joint replacement (i.e., cost-utility) in randomized clinical trials where hip and knee 
patients were followed from baseline to one year after the TJR. Several studies have 
been published about the effect of waiting time on HRQoL in patients waiting for TJR,
and use of quality-adjusted life years (QALYs) for estimating the effectiveness of health
care. Earlier systematic literature reviews from Ethgen et al. (2004) and Hoogeboom 
et al. (2009) have been published relating to these outcomes. 
3.1 Results from the earlier systematic literature reviews 
The objective in a systematic literature review of Ethgen et al. (2004) was to review 
the literature regarding the outcomes of total hip and knee arthroplasty as evaluated 
by HRQoL instruments. In this review, the Medline and EMBASE medical literature 
databases were searched from 1980 to 2003, with the following terms: hip and knee 
arthroplasty/replacement, quality of life and outcomes. The findings of this systematic
review, related to our study were: 
Total hip replacements (THRs) and total knee replacements (TKRs) were found to 
be effective in terms of HRQoL improvement. When improvement was found to be 
modest, the role of co-morbidities was highlighted. Further, when patients reported 
poorer preoperative HRQoL, they were more likely to experience greater improvement.
A longer waiting time did not necessarily diminish the potential improvements that 
patients could achieve with surgery. Shortening the waiting times and prioritizing 
patients in terms of severity would serve to reduce the burden of waiting for surgery 
(Ethgen et al. 2004). 
Most of the studies of the review of Ethgen et al. were observational studies rather 
than randomized controlled studies. According to this review, no studies have fully 
investigated the effectiveness of THR and TKR compared to non-operative care. Yet 
there were studies where patients were randomized with respect to different prosthetic
types. 
The objective in the systematic review of Hoogeboom et al. (2009) was to describe 
changes in pain and functioning in patients with OA awaiting TJR and to assess de­
terminants of this change. In this review, the Medline, Embase, Cinahl and Cochrane
databases were searched from 1999 through June 2008. 
The main results of this review indicated that there was strong evidence that pain 
and perceived functional status did not deteriorate in patients waiting for major joint 
replacement during a period less than 6 months. Conflicting evidence was found for 
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the change in self-reported functional status while waiting less than 6 months for TKR.
Hoogeboom et al. concluded that there were only a few high-quality studies examin­
ing the effect of long waiting times (≥ 180 days) on pain and functioning. Only six 
randomized clinical trials were reported including Hirvonen et al. (2007a), using data
from this study and five other studies from preoperative exercises and rehabilitation. 
3.2 Literature review 
The present review of the literature published from 2002 to 2009 was carried out first 
in 2009 and re-run in 2011 using the PubMed, Cinahl, Medic, Arto and Linda and 
SweMed databases. The following search terms were used: randomization, waiting 
time, waiting list, hip, knee, HRQoL, cost-effectiveness, cost-utility, health care costs,
arthroplasty/total joint replacement. The first selection was based on the contents of 
the abstract. Result of the present literature review is presented in Figure 2. 
Figure 2. Flow diagram for study selection. 
Literature review 
I 2009 
II 2011 
Medline 1
Publications = 17 
Swe Med 
Publications = 25 
Stakes Lib 
Publications = 2 
Selected publications = 5 
Selected
publications = 0 
Selected
publications = 0 
EMBASE 
Medline 2 
Publications = 15 
Selected
publications = 3 
Other founded
publications = 1 
Publications 80; Selected to this review 11 
EMBASE 
Cinal 2 
Publications = 21 
Selected
publications = 2 
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Studies were eligible for inclusion in the review if: (1) the data were prospective in na­
ture and the waiting time was measured, (2) generic and disease-specific instruments 
were used to measure HRQoL, (3) the cost-effectiveness or costs related to waiting 
time or TJR were calculated, and (4) follow-up time was at least three months. A total 
of 80 studies were found, of which 69 were excluded because they did not contain 
all the main criteria, which were: randomization, waiting time, HRQoL and costs 
related to total joint replacement of hip and knee patients. In addition, six of these 
were our own studies from the same data and were excluded (Hirvonen et al. 2006, 
2007a, 2007b and 2009; Tuominen et al. 2009 and 2010; articles II and III included in 
this thesis). The present literature review contains 11 studies. 
3.2.1 Results of the present literature review 
There were no randomized studies about cost-effectiveness/cost-utility related to dif­
ferent waiting times. The costs related to osteoarthritis were calculated in 11 studies, 
the direct costs of hospital stay and prosthesis in two studies (Fielden et al. 2005; 
Núñez et al. 2007), and seven evaluated the cost-effectiveness of the surgery (Segal 
et al. 2004; Brauer et al. 2005; Brunenberg et al. 2005; Räsänen et al. 2007; Navarro 
Espigares et al. 2008; Xie et al. 2009; Higashi et al. 2011). The effect of waiting time on 
HRQoL and costs were addressed in 2/11 studies. The follow-up time from baseline, 
when patients were placed on the waiting list up to 12 months, was in the studies of 
March et al. 2002; Brunenberg et al. 2005; Xie et al. 2009; and Higashi et al. 2011. The 
main findings of the present literature review are summarized in Table 3 (pp. 24–25). 
Outcome measurements 
Both generic and disease-specific quality of life instruments were used. The EQ-5D 
(4/10), SF-36 (4/10), AQoL (1/11) and 15D (2/11) were used to measure HRQoL. Pain 
and function of hip or knee patients were measured by the WOMAC (4/11), Harris Hip
Score (HHS), and Knee Society Rating System (KSS score) used in the four studies. 
The EQ-5D, AQoL and 15D are generic Multi-Attribute Utility (MAU) instruments, 
designed to generate a single index value for each health state (Hawthorne et al. 2000).
The aim of these instruments is to provide a standardized, non-disease-specific survey
instrument and generate a cardinal index of health. The fully scaled MAU instru­
ment may be used to estimate the utility of all possible health states (Hawthorne et al. 
2000; Bowling 2005). The Short Form-36 health survey questionnaire (SF-36) is the 
most frequently used HRQoL instrument. It consists of 36 health-related questions. 
The SF-36 is a profile instrument and thus does not belong to the category of instru­
ments producing a valuation-based single index number (Bowling 2005), although a 
valuation algorithm has been elicited to also generate a single index number (SF-6D) 
(Brazier et al. 2007). 
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The Western Ontario and McMaster Universities OA index (WOMAC) is the most 
used proprietary set of standardized condition-specific instruments to evaluate pa­
tients with OA of hip or knee, including pain, stiffness, and physical functioning of 
the joints. When used in clinical studies, the WOMAC pain and function subscales 
perform comparably or better than other tests in being responsive to change from 
experimental interventions, but this varies for the different subscales and ty pes of 
intervention. The Western Ontario and McMaster Universities OA index (WOMAC) 
is the most used condition-specific instruments for the assessment of hip or knee OA 
and is recommended by OMER ACT (Outcome Measures in Rheumatology Clinical 
Trials) (American College of Rheumatology 2012). 
The effect of waiting time on HRQoL and costs of TJR 
In the studies of March et al. (2002) and Fielden et al. (2005, where the length of waiting
time was measured, the effect of waiting more than six months was associated with 
higher total mean costs than waiting less than 6 months and led to poorer physical 
function before the operation. Furthermore, patients with poor health status showed 
greater improvements in pain and physical function and HRQoL after the intervention
(Fielden et al. 2005 Räsänen et al. 2007; Navarro Espigares et al. 2008; Hawker et al. 
2008; Montin et al. 2009; Higashi and Barendregt 2011). Six studies also determined 
the economic and health outcomes of waiting in hip or knee patients. The incremental
cost-effectiveness ratio (ICER) was calculated in five of these studies and suggested 
that TJR was a highly cost-effective procedure. None of these studies evaluated the 
differences between short (< 3 months) and longer (> 3 months) waiting times. 
The interest in evaluating cost-effectiveness and the effect of waiting time is increas­
ing. Most of the studies are before-after studies and the follow-up times are short. 
For clinical outcomes, randomized controlled trials are the standard and accepted 
approach for evaluating interventions. Pragmatic randomized trials provide a suit­
able environment not only for assessing clinical effectiveness but also for comparing 
costs. Carrying out an economic evaluation alongside a randomized controlled trial 
allows detailed information to be collected about the amount of resources used by 
each patient. This information allows an estimate of the cost of treatment for each 
individual patient, producing a set of cost values, which will be referred to as patient­
specific cost data (Barber and Thompson 1998). 
Randomizing patients in clinical trials is not novel. But according to earlier system­
atic literature reviews, no earlier studies have been published with randomization of 
patients waiting for surgery, one year postoperative follow-up, and analysis based on 
the intention-to-treat (ITT) principle. 
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4 WAITING TIME AND ACTIONS TO SHORTEN IT 
4. 1 Access to care 
It is a common assumption that long waiting times for elective surgery are a heav y 
burden both to patients and those who deliver health care services. The municipali­
ties are under pressure from both sides (supply and demand) because of the lack of 
health care resources to reduce long waiting lists. 
Access to care at hospitals is usually managed by scheduling demands for service. In 
the scheduling of surgical demand, the patients available for the next service period 
are identified, and hospital resources are reserved to ensure appropriate care before 
and after an instance of surgery. Within services, patients are selected from waiting 
lists and scheduled for surgery on the basis of urgency, best use of allocated operating 
time, and availability of hospital resources (Sobolev and Kuramoto 2008). 
Patients are placed on a wait list after the decision to perform surgery is made. Before 
being added to the operating room schedule, each patient is assessed by his or her 
surgeon to determine suitability for the surgery. If a patient is deemed unfit, sched­
uling of the operation may be postponed. Scheduling the operation may be delayed 
for a number of reasons: the patient decides to postpone the surgery, the hospital 
ward or operating room is unavailable at the scheduled time, or the doctor decides 
to send the patient for additional preoperative investigation. Also the patient may die 
or their condition deteriorates or the operation becomes unnecessary (Sobolev and 
Kuramoto 2008). 
What is the optimal waiting time? There is inconsistent scientific evidence on whether
there is a relationship between the length of waiting time and the outcomes of the 
surgery in terms of cost-utility. In agreement with Siciliani and Hurst (2003), the opti­
mum waiting time will not be zero. It can be cost-effective to maintain short queues of
elective patients because the adverse health consequences of short delays are small and
because there are savings in hospital capacity from allowing queues to form (Siciliani 
and Hurst 2003). A simple criterion has been proposed that waits should be reduced 
until the costs of doing so exceed the benefits (Schaafsma 2006), and Siciliani and 
Hurst defined an optimal waiting time where the costs and benefits of making further
reductions were equal (Harrison and Appleby 2010). Figure 3 (p. 28) describes the 
hypothesis of Siciliani and Hurst on the effect of different waiting times on the health 
benefits and costs of surgery. The mean waiting time (W) is shown on the horizontal 
axis; the total benefits and costs of surgery are on the vertical axis. The total benefits 
of surgery will be constant at a given rate of surgery, which might, or might not, be 
the optimum rate. That is because waiting times can only be varied for a given rate of 
surgery if surgeons vary their clinical thresholds for admitting patients on lists. This 
will not in itself affect benefits because changes in formal waiting must be offset exactly
by equal and opposite changes in hidden waiting. Only if the surgery rate changes will
the benefit curve depicted in Figure 3 change, shifting upwards or downwards. The 
total costs of supplying surgery for different waiting times are assumed to be roughly 
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in a U-shape. Costs fall as waiting time increases, and there can be savings in surgi­
cal capacity if a waiting list is formed and additional elective patients are called in 
for treatment when there are lulls in the flow of emergency patients. This reduces the 
probability that supply exceeds demand, leaving capacity unused. Furthermore, the 
administrative costs of a waiting list will increase with the length of the waiting time 
and waiting lists as will the diversion of clinical resources to a regular reassessment 
of patients on the list. Beyond a certain point, rising administrative and clinical costs 
are likely to outweigh falling capacity costs as the length of the list increases (Iversen 
1993; Siciliani and Hurst 2004). 
Figure 3. Optimal waiting time W
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. 
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Source: Siciliani and Hurst 2004. 
However, there is little scientific evidence about the relationship of length of the wait­
ing time and cost-effectiveness of elective surgery. 
4.2 Waiting time and health care reforms 
When comparing surgical procedures, Finland, England and Sweden have been the 
countries with the longest waiting times (Siciliani and Hurst 2003). Because of the 
long waiting times for elective surgery, health care reforms have come into force in 
recent years. The primary aims of these reforms were to reduce and equalize waiting 
times for the selected treatments (Hanning and Winblad Spångberg 2000). Some
countries have explicit waiting time prioritization, recommended admission within 
a certain time period, or priority scoring systems, points for patients, for elective 
surgery (Gravelle and Siciliani 2008). 
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4.2.1 Health care reforms in England and Sweden 
The health care reforms have a long history. Since the establishment of the National 
Health Service (NHS), the British Government has introduced a large number of 
health care reforms. The main objectives have been to: reduce waiting times, increase 
productivity, improve indicators of health outcome, improve quality and reduce in­
equalities in health across socio-economic groups and across regions with the worst 
and best health outcomes indicators (Hagen and Kaarbøe 2006; Oliver 2006). 
One of the latest implementations in health care in England is benchmarking for 
acceptable waiting time. There is a timeframe to represent a goal, target or standard 
for the length of waiting time for a specified service. There are financial incentives 
based on performance, further increasing capacity of hospitals, equipment’s and staff,
booking systems, nationally consistent prioritization of patients, improving commu­
nication between specialists and hospitals, and giving patients certainty of treatment 
and choices if the benchmarking is not met. There is consistency across benchmarks 
specifically for hip and knee replacements for waiting times to be no longer than 6 
months (Noseworthy et al. 2005). 
Between 2000 and 2005, the main focus in English government policy was to reduce 
waiting times for inpatient services and the first outpatient appointment with ex­
plicit targets: the major emphasis being on more choice by patients. Extra funding 
was provided, and hospitals were directly managed towards published targets. The 
aggressive deployment of robust performance management system alongside targets, 
and increasing funding appeared to be a success in reducing waiting times in England
(Wilcox et al. 2007). 
The health care system in Sweden, as in Finland, is financed primarily through taxes 
levied by county councils and municipalities (Swedish Association of Local Authori­
ties and Regions 2005; Albin et al. 2010). In 1992, the Swedish government issued a 
3-month treatment guarantee for ten elective treatments with long waiting times (e.g. 
cataract surgery and hip replacements). If the county council could not provide treat­
ment within 3 months, the patient was to be offered treatment at a hospital in some 
other county council or at a private hospital. The national government supported 
the guarantee with additional funding, which made the task easier and waiting lists 
shortened temporarily. 
In 1997 a new reform came into force, where health care should give priority to patients
with greater needs (Anell 2005). According to Anell (2005), there was an obvious dif­
ficulty in instituting a reform that takes into account all relevant health care objec­
tives simultaneously, which may be linked to a pattern of political decision-making. 
New policies in Swedish health care have tended to focus on one objective at a time, 
reflecting the most urgent problem. Furthermore, every new reform thereafter carries
a seed of new problems, generating demand for additional change. 
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4.2.2 Health care reform in Finland 
A national project to ‘Ensure the Future of Health Care in Finland’ was commenced 
in 2001 by the Finnish government to reform and develop health care services in the 
country. This induced the Finnish government and local authorities to adopt a new 
plan and funding arrangements for the Finnish health care system. New health care 
reform was instigated in 2005, the year of the present study. The target of this reform 
was to reduce waiting times and guarantee equal access and to develop criteria for 
non-urgent care (e.g. hip and knee replacements) in a reasonable time period for all 
citizens. The following recommendations for access to care were made: 1) patients 
contacting health centres should be assessed by a doctor or other health professional 
within three days; 2) patients requiring assessment by a specialist should be offered 
an appointment within three weeks; 3) recommended hospital treatment, including 
elective surgery, should be offered within six months (Ministry of Social Affairs and 
Health 2004). 
Before the reform came into force, the state together with municipalities gave extra 
financing to hospital districts in the sum of EUR 50 million during 2003–2004 to 
decrease long waiting times in specialised medical care. Despite the extra money, the 
waiting times were still long in 2004 and 2005. The information on waiting times and 
queues for surgery was not transparent before the waiting time reform. When the 
reform came into force on 1 March 2005, the state started an efficient monitoring of 
queues in the hospital districts (Mikkola et al. 2008). 
The Finnish health care sector invested EUR 382 million (EUR 72 per capita) in
2002–2007 to reach the waiting time targets. A peak year was 2005, when around 2.3%
of health spending by municipalities was devoted to waiting-time reform. Investment
declined gradually to 0.9% in 2007. Around 69% of extra money due to waiting time 
reform went to hospitals and 31% went to health centres (Mikkola et al. 2011). The 
waiting times for most queued operations decreased slightly, but in 2006 the decrease 
was more extensive, and the number of elective patients that had waited longer than 
6 months decreased by 42% (Mikkola et al. 2008) compared to earlier years. 
According to international and national experiences, the waiting time reforms have 
been more or less successful, and a lot of effort is still needed to solve the problems of 
long waiting times and differences in treatment practices. It is important to identif y 
cost-effective strategies for managing OA patients, i.e., to maximise health benefits 
given the limited health care resources. 
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5 ECONOMIC EVALUATION
5.1 Economic evaluation in health care 
The goal of treatment is not only to prolong life, but also to contribute to well-being. 
The rising burden of chronic diseases puts pressure on societies to find more effec­
tive and cost-effective ways to improve citizens’ health in circumstances of strict
budgeting and cost control. For allocating resources, national political planning and 
international organisations need evidence of the impacts of interventions (Bowden and
Fox-Rushby 2003). To facilitate the comparison of different interventions, measures 
have been developed to bring together clinical, quality-of-life, and economic outcomes
in summary measures such as quality-adjusted life-years (QALYs), cost-effectiveness, 
and cost-utility ratios (Lyman 2001). 
Economic evaluation is the comparative assessment of the costs and benefits of alterna­
tive health care interventions (Drummond et al. 2005; Brazier et al. 2007). Interven­
tions that are associated with large or uncertain resource consequences and small or 
unclear efficacy are most likely to be candidates for economic analysis. There are four 
main forms of economic evaluations, each dealing with costs, but differing in the way
that the consequences of health care programmes are measured and valued (Table 4). 
Table 4. Measurement of costs and consequences in economic evaluation. 
Type of study
Measurement / 
valuation of costs
in both alternatives Identifications of consequences 
Measurement / 
valuation of consequences 
Cost analysis Monetary units None None 
Cost-effectiveness
analysis 
Monetary units Single effect of interest, common to 
both alternatives, but achieved to 
different degrees 
Natural units 
(e.g. life-years gained) 
Cost-utility analysis Monetary units Single or multiple effects, not neces­
sarily common to both alternatives 
Healthy years (quality­
adjusted life years, OALYs) 
Cost-benefit analysis Monetary units Single or multiple effects, not neces­
sarily common to both alternatives 
Monetary units
Source: Drummond et al., 2005. 
5.1.1 Quality-adjusted life year 
A quality-adjusted life-year (QALY) takes into account both the quantity and qual­
ity of life generated by health care interventions. It is the arithmetic product of life 
expectancy (a measure of the remaining life-years), and it reflects the change in sur­
vival with a weighting factor for quality of life. A QALY places a weight on time in 
different health states. A year of perfect health is worth 1 and death is considered to 
be equivalent to 0. The QALY provides a common currency for measuring the extent 
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of health gain that results from health care interventions and when combined with 
the costs associated with their relative worth from an economic perspective (Bowl­
ing 2005; NICE 2009). Figure 4 presents a situation where Intervention I provides a 
consistently greater area under the QALY time curve than Intervention II. 
Figure 4. QALYs gained from Intervention I in comparison to Intervention II (area between the curves). 
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Source: Drummond et al. 2005. 
5.1.2 Cost-effectiveness analysis 
Cost-effectiveness analysis (CEA) is a method designed to assess the comparative 
inputs of expenditures and effectiveness from different health interventions. It is
based on the premise that “for any given level of resources available, society wishes 
to maximize the total aggregate health benefits conferred” (Gold et al. 1996; Drum­
mond et al. 2005; Brazier et al. 2007). 
The central measure used in CEA for comparing two alternatives is the incremental 
cost-effectiveness ratio (ICER), where the difference in their costs is divided by the 
difference in their effectiveness. When one of the alternatives (intervention) is both 
more effective and less costly than the comparator, then it strongly dominates the 
other alternative (Gold et al. 1996; Drummond et al. 2005). Where the benefits of 
competing alternatives can be measured along a single dimension, then CEA can be 
used to rank interventions in terms of their ratio of cost per unit of effect. Effects are 
usually measured in natural units (Gold et al. 1996). 
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5.1.3 Cost-utility analysis 
Cost-utility analysis (CUA) is a form of evaluation that focuses on the quality of the 
health outcome produced by health programmes or treatments. It has many similarities
to CEA. In CUA, the incremental cost of a programme from a particular viewpoint 
is compared to the incremental health improvement attributable to the programme, 
where the health improvement is measured in QALYs gained. The comparison is pos­
sible if the measure of effectiveness is general enough to capture all of the important 
health dimensions of the effects of the interventions. The results are expressed as a cost
per QALY gained. In the QALY approach, the quality adjustment is based on a set of 
values or weights called utilities (one for each possible health state), which reflect the 
relative desirability of the health state (Drummond et al. 2005.) CUA distinguishes 
between those studies that use a generic outcome measure and are potentially compa­
rable across studies. It highlights the crucial role of consumer preferences in valuing 
the outcomes (Drummond et al. 2005.) 
5.1.4 Decision rules of CEA and CUA 
To decide which of the evaluated interventions is cost-effective, both costs and conse­
quences have to be compared. There are nine different situations to take into account 
when making this decision about cost-effectiveness (Table 5). 
Table 5. The cost-effectiveness decision table. 
A new intervention 
compared with 
an old Less effective Same effectiveness More effective 
Less costly No clear decision 
(no dominance) 
Incremental analysis needed 
The new intervention, 
the new dominates the old 
(weak dominance) 
The new intervention, 
the new dominates the old 
(strong dominance). 
Same costs Keep the old intervention, 
the old dominates the new 
(weak dominance) 
The interventions are equal Opt for the new intervention, 
the new dominates the old 
(weak dominance) 
More costly Keep the old intervention, 
the old dominates the new 
(strong dominance) 
Keep the old intervention, 
the old dominates the new 
(weak dominance). 
No clear decision 
(no dominance) 
Incremental analysis 
needed 
Source: Drummond et al. 2005. 
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In two of the nine situations described in Table 5, there is no dominance and incre­
mental analysis is needed, i.e., the ICER needs to be calculated. The new intervention 
is considered cost-effective if the society is willing to pay for the additional benefits or 
if the society considers that the cost savings compensate for the lower effectiveness. 
The concept of the value of a QALY has reached prominence in policy and in empirical
research due to the creation of national-level health technology assessment agencies. 
When assessing particular interventions in terms of health gains against the costs of 
provision, such agencies must in effect put a monetary value on those health gains. In 
the context of England, where the National Institute for Health and Clinical Excellence
(NICE) uses the QALY as its health metric, NICE must decide what value(s) of a QALY
to use (Brazier et al. 2007; Donaldson et al. 2005. Since the inception of NICE, the 
threshold value of the QALY gained has been £20 –30,000 (EUR 24–33,000) (Rawlins 
and Culyer 2004). In Finland, there is no common agreement on the monetary value 
for QALY gained. 
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6 AIMS OF THE STUDY 
The overall objective of this study was to evaluate the effect of waiting time on health 
outcomes and costs of total joint replacement in hip and knee patients before and after
the operation. In more detail, the main questions addressed were: 
1) Does co-morbidity affect the HRQoL in patients awaiting major joint replacement?
(Paper I). 
2) Does the length of waiting time have an effect on health outcomes, use and costs of
medication in hip replacement patients during the follow-up time from baseline 
to 12 months postoperatively? (Paper II). 
3) Is the longer waiting time associated with quality of life outcomes and costs of
medication in knee replacement patients during the follow-up time from baseline
to 12 months after the operation? (Paper III). 
4) Is it possible to improve the cost-utility of major joint replacement by shortening
the waiting time? (Paper IV) 
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7 PATIENTS AND METHODS 
7.1 Study design 
This study is a prospective randomized controlled trial (RCT), where effects of the 
different lengths of waiting time on health outcomes and costs were evaluated. Pa­
tients placed on the waiting list for TJR were randomly allocated to different waiting 
time groups: an intervention group (patients in short WT group, SWT, waiting time 
≤ 3months) and a control group (patients in a non-fixed WT group, NFWT, waiting 
time > 3 months). Patients were followed in the randomized groups according to the 
ITT principle through the whole follow-up time. 
7.2 Feasibility of the study 
Four surgical hospitals were chosen from southern Finland. However, one of the hos­
pitals was neither included in the randomization procedure nor in the final analyses 
because in that hospital patients waited less than three months any way. Several ar­
rangements were made to create a functional and equal procedure for all patients. 
In surgery, randomization is not novel, but when stepping in to the hospital routine 
procedure by selecting (randomizing) patients who were placed on the waiting list, the
situation was different. The key persons to recruit the patients after the TJR decision 
were the practise surgeon and the nurse. In each hospital, we had a named nurse who 
was a person in charge. Common guidelines for administering the questionnaires 
were provided in each hospital, and the procedure was weekly under supervision by 
a researcher. We had some difficulties at the beginning. Some surgeons did not allow 
their patients to participate in the study, some nurses were unwilling to recruit the 
patients, and some patients were unwilling to fill in the questionnaires four times 
during the observation period. 
7.3 Study population 
Between August 2002 and November 2003, 1,236 consecutive osteoarthritis patents 
were informed about the study in four Finnish hospitals and were invited to participate.
Two of the hospitals (the Surgical Hospital and Jorvi Hospital) are part of the Helsinki
University Central Hospital, the third is the Coxa Hospital for Joint Replacement in 
Tampere, and the fourth is Orton Orthopaedic Hospital in Helsinki. Of these eligible 
patients, 168 were from Orton Orthopaedic Hospital and 1,068 patients were from 
the other three hospitals. 
The patients came for an outpatient surgical assessment by referral from a health care 
centre, a local central hospital, or a private physician and were recruited to the study 
when placed on the waiting list through contact with orthopaedic and practice staff. 
They were recruited to the study in three recruitment periods (for the Coxa Hospital 
for Joint Replacement) or four (for the other two hospitals), each period lasting three 
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months. In Orton Orthopaedic Hospital, there was only one recruitment period, and 
patients were not randomly assigned to either of these groups because surgery per­
formed according to the hospital’s routine procedure was done in less than 3 months. 
The last patient was admitted to the hospital in May 2005. 
The key inclusion criteria were: (1) need for a primary total joint replacement due 
to severe osteoarthritis of hip or knee joint as evaluated by the hospital surgeon; (2) 
patient was an adult, aged 16 or older; (3) patient was placed on the waiting list in a 
research hospital; and (4) patient was willing and mentally able to participate in the 
study. The key exclusion criteria were patients with rheumatoid arthritis, fractures, 
and congenital haemophilia or congenital deformities. 
According to the randomization protocol, a total of 1,068 osteoarthritis patients was 
informed about the study and asked to participate. Of the eligible patients, 235 (22%) 
were excluded, 206 patients refused to participate, 4 did not understand Finnish or 
Swedish, 2 were operated on the contralateral side, one was an inmate at an institu­
tion, and 22 for unknown reasons. A total of 833 patients were randomized, and of 
these, 550 (66%) patients completed all four questionnaires and were included in the 
final cost-utility analyses. At baseline, 893 non-randomized patients from all four 
research hospitals were included in the co-morbidity study (Study I). This selection 
is not shown in the patient flow. (Figure 5, p. 39.) 
7.4 Randomization of the study population 
Patients were recruited to the study in three recruitment periods (for one of the hos­
pitals) or four (for the other two hospitals), each period lasting three months to avoid 
the waiting time for the SWT group exceeding three months. Patients randomized into
the SWT group were operated within two weeks following the end of each recruitment
period. As only half of the hospital’s one-month surgical capacity could be allocated 
to the SWT group, the number of SWTs was restricted and determined specifically 
for each hospital. The size of the NFWT group was not restricted so as to ensure that 
all eligible patients placed on the waiting list had an opportunity to be recruited to 
the study. The two patient groups therefore differed in size. 
Computer-generated randomization sequences were produced by the National Re­
search and Development Centre for Welfare and Health and supplied to the hospitals 
using consecutively numbered and sealed opaque envelopes. The patient’s named nurse
assigned participants to their groups after the decision for surgery had been made. The
randomization envelopes contained information on whether the patient belonged to 
the SWT group or the NFWT group. Surgeons were blind to patient allocation. For 
ethical reasons, double-blinding was not possible. 
Each patient provided informed consent and completed a self-administered question­
naire when placed on the waiting list, at admission and at three and twelve months 
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postoperatively. The questionnaires were either distributed to the patients at the hos­
pital or in some cases mailed to patients, as happened with one hospital for the third 
and fourth questionnaires. All questionnaires were returned by post. The number of 
patients placed on the waiting list varied from one month to another, being specific 
to each hospital. Therefore, no advance estimate could be made of the number of 
patients to be placed on the list. The data collection was successfully completed. The 
flow of patients is presented in Figure 5. 
In this study, standard analysis for randomised groups were made according to the 
intention-to-treat (ITT) principal. The procedure gives a valid estimate of the effect of
intervention assignment on outcome (Mealli and Li 2011). This form of data analysis 
provides a strategy for analysing data, in which all participants are included in the 
treatment group to which they were originally assigned at randomization. 
As a secondary analysis, we used per-protocol analysis. It is an alternative approach 
that compares those who were assigned to and received treatment with those who 
were assigned to and received control, i.e., compares those who appeared to comply 
with the protocol and completed the treatment as originally allocated (Mealli and Li 
2011; Shah 2011). 
7.5 Outcome measures 
7.5.1 Generic 15D instrument 
HRQoL was measured by the generic 15D instrument. The 15D is composed of 15 
dimensions: moving, vision, hearing, breathing, sleeping, eating, speech, excretion, 
vitality, usual activities, mental function, discomfort and symptoms, depression,
distress, and sexual activity. Each dimension has 5 ordinal levels to choose from. 
The 15D can be used as a profile measure or to give a single index score by means of 
population-based preference weights. The index score (15D score) ranges from 0 (dead)
to 1 (completely healthy). Completing the 15D questionnaire takes 5 to 10 minutes, 
and it describes the HRQoL of the respondent at present. A difference of > |0.03| in 
the 15D score is clinically important in the sense that on average people can feel the 
difference (Sintonen 1994a and 2001). 
The 15D has been used successfully in earlier studies dealing with hip and knee re­
placement and thus facilitates the comparison to the pre-surgery scores in these studies
(Rissanen et al. 1995; Räsänen et al. 2005; Hirvonen et al. 2006). There is earlier evi­
dence that in most of the important properties (reliability, content validity, sensitivity
in terms of discriminatory power, and responsiveness to change), the 15D compares 
at least equally with other similar instruments that produce a valuation-based single 
index number (Stavem 1999; Sintonen 2001; Hawthorne et al. 2001; Drummond et 
al. 2005; Brazier et al. 2007; Mook and Kohlmann 2008). 
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Although the SF-36 (Short Form 36) has been widely used in the OA area, it is basically
a profile instrument and thus does not belong to the category of instruments produc­
ing a valuation-based single index number. However, in 1998, the first algorithm was 
published to generate a valuation-based single index score (the SF-6D score) from the 
SF-36. The paper by Hawthorne et al. (2001) showed that the 15D performed at least 
as well as the SF-6D, if not better. Recent research with that algorithm indicates that 
especially in the rehabilitation of musculoskeletal disorders, the 15D was at least as 
responsive as the SF-6D, if not better. These two instruments were any way the most 
responsive ones (Moock and Kohlmann 2008). 
The scores of 15D are suitable for QALY calculation. In this study, QALYs during the 
equally long follow-up time was calculated by the following formula (knee patient): 
QALY = [0.5 (a  b)*h  + 0.5 (b + c) *h + 0.5 (c  d)*h ] / 12 
SWT + 1 2 + 3
were a, b, c and d are the mean values of the 15D score at different measurement points
(a = baseline, b = at admission, c = three, and d = 12 months after the surgery) and 
h
1
 is the mean waiting time in months, h
2 
is the time form admission (three months) 
and h
3 
is the total follow-up time (in SWT 14 months, and in Nf WT nine months, up 
to 20 months in both groups). 
7.5.2 Disease-specific outcome measures 
Disease-specific quality of life instruments contain a list of symptoms relevant to 
the condition under study. One of the disease-specific instruments in hip patients is 
the Harris Hip Score (HHS). In this study, HHS was modified and used to measure 
hip pain and function as a supplement to generic 15D. The self-report HHS consists 
of two sections: pain (0 –44 points) and functional activities of daily living and gait 
(0 –47). The total score ranges from 0 to 91, with higher scores representing better 
health states (Harris 1969. A further 9 points of the total Harris Hip Score would 
normally be assigned to describing deformity and range of motion, but were excluded 
because these items could not be measured in a patient self-report questionnaire. The 
performance of self-reported HHS is comparable to that of surgeon-assessed HHS 
and has shown to be less burdensome to patients than a physician-administered HHS 
(Mahomed et al. 2001). 
For knee patients, the self-report Knee Society Clinical Rating System (KSS) was
chosen. KSS has been shown to be more responsive as a measurement of standard­
ized response in pain and function domains than WOMAC and SF-36 (Lingard et 
al. 2001). In this study, KSS was used as modified to measure knee pain and physical 
function (Insall et al. 1989; Lingard et al. 2001). Functional performances were as­
sessed using walking distance and stair climbing. The pain score (0 –50 points) and 
function score (0 –100 points) are presented separately; clinical dimensions (range of 
motion, stability, flexion contracture, extension lag and alignment was 30% of the 
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total score) could not be measured in a patients’ self-administered questionnaire, and 
thus the total score could not be derived. 
7.5.3 Direct rating scale instrument 
To evaluate the patients’ sense of well-being, a Visual Analogue Scale (VAS – a health­
state rating scale) was used. The measurement consists of a line on a page with clearly 
defined endpoints. The distance between intervals on a VAS should reflect a person’s 
understanding of the relative difference between the concepts being measured. VAS has
been used in the context of health as a measure of symptoms and domain of health, and
to provide a single index measure of HRQoL. The most preferred health state is placed
at one end of the line and the least preferred at the other end (McDowell and Newell 
1996; Drummond et al. 2005; Brazier et al. 2007). In this study, VAS was a horizontal 
line (100 mm = 100%) illustrating the total of the patients’ health state deficiency at 
that moment. It was used to value the effect of arthritis on this deficiency of health. 
Patients were asked to mark on the line which part of the deficiency of health is due 
to arthritis. The higher the number was, the more powerful was the effect of arthritis.
In addition, the patients’ self-reported state of health was described on a five-point 
scale, representing health states from excellent to bad. 
7.6 Direct cost measures 
7.6.1 Social and health service use 
It is a common assumption that patients having OA use more health and social ser­
vices than the same-age population without OA. Data on the use of social and health 
services due to OA were collected using a self-administered questionnaire delivered 
to patients at the hospital and via the post. Participants were asked whether they had 
had home visits from a nurse, chiropodist or physician and whether they had used 
rehabilitation services within three months due to OA. In addition, patients were 
asked whether they had used any support services of home help, including regular or 
temporary meals-on-wheels, housework, laundry services, bathing or transportation. 
In addition, patients were asked whether they had physician visits to a university 
hospital, central hospital, regional hospital, health care centre, private physician or 
occupational health care visits, and how many hospital days they have had due to 
OA. The use of services in the previous three months due to OA was measured when 
placed on the waiting list, on admission, three months and one year after operation. 
The costs related to TJR consist of the use of hospital care costs (total costs of hospital 
services, including TJR, paid by purchaser). The total direct costs during the wait­
ing time and after the surgery include the following items: outpatient visits (doctor, 
nurse, and chiropodist), costs of the surgery including radiology, laboratory services, 
hospital days and rehabilitation services. The use and costs of regular social services 
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due to OA including meal-on-wheels, home help, laundry services, bathing services 
and transportation during the waiting time were included. 
The mean number of service use was calculated and the mean costs of use were cal­
culated. Costs of social and health services were valued in Finnish unit costs in 2006 
(Hujanen et al. 2008.) The costs of TJR were obtained from FHDR (HILMO) and cost 
data were linked to the collected patients’ data. 
7.6.2 Medication use 
The goal of medication to OA is to reduce the symptoms, namely joint pain, stiffness, 
and swelling. Drugs are also used postoperatively as pain killers. To get this medica­
tion information, we asked patients to report the name and dosage of the medication, 
which they used due to OA. Because of the circumstances mentioned before, reporting
was very heterogeneous. However, the main stream of medication was observed. The 
unit costs of medication per tablet were obtained from CD-Pharmacy (Pharmaceuti­
cal Information Centre in Finland 2004). In this study we did not separate different 
medication groups related to OA; disease-specific medication (DSM) was used as a 
key word. The costs of DSM during the observation period were calculated as product 
use per week. The calculations were made at each of the four measurement points. 
7.7 Statistical analysis 
In this study the sample size estimate was based on the primary outcome variable of 
the 15D score. A subgroup of 177 patients would provide the 80% power (two-tailed α 
error 5%) to detect a clinically important difference (Δ0.03) in the 15D score between 
the randomized groups (Sintonen 1994b). At baseline (when placed on the waiting 
list), descriptive statistics were used to describe the socio-demographic and clinical 
characteristics and differences in the co-morbidity groups and randomized patient 
groups. Comparative variance analyses of socio-demographic and clinical charac­
teristics were carried out using either an independent samples t-test or a Chi-square 
test depending on whether the variable was on a continuous or a nominal scale. The 
differences on each of the 15D dimensions and in the overall 15D single index score 
for patients were calculated. 
Primary analyses were conducted with an ITT principle (Mealli and Li 2011) so that 
patients were followed in the groups to which they were randomly allocated. Also a 
supplementary per-protocol analysis was carried out first at admission by excluding 
the patients in SWT group who were admitted beyond the short waiting time (wait­
ing time > three months), and secondly when the cost-utility of waiting time was 
evaluated with patients who were treated according to the time limits of the group to 
which they were randomized. 
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When comparing the effect of waiting time on the mean scores of 15D, total HHS, 
pain, function in knee patients and costs of DSM at the various points of follow-up 
between SWT and Nf WT, a general linear model for repeated measures was used. 
Univariate (tests of within-subject effects) p-values were calculated, while a p-value 
< 0.05 was considered statistically significant. The results for estimated effects were 
given as mean differences, standard deviations and 95% confidence intervals (CI) for 
the score of 15D, total HHS, pain, function and costs of DSM. 
Missing data on the 15D questionnaire were predicted by means of a regression model
with the patient’s responses for other dimensions, and also with other data from the 
patients, as age and gender as explanatory variables (Sintonen 2001). The missing 
data were replaced if a minimum of 80% of the dimensions had been completed. 
Furthermore, the incidence of co-morbid diagnoses and also the mean 15D score 
were calculated for each co-morbidity group in the model. 
To assess the degree of uncertainty in the results of cost-utility analyses, probabilistic 
sensitivity analyses (bootstrapping with 1,000 replicates) were carried out. Results 
are given as mean incremental costs and effects with their 95% confidence intervals, 
incremental cost-effectiveness ratio (ICER), cost-effectiveness plane (CE plane) and 
cost-effectiveness acceptability curve (CEAC). 
The CE plane was presented to show how decisions can be related to both costs and 
QALYs. The plane is divided into four quadrants indicating four possible situations 
relating to additional costs and additional QALYs associated with the SWT compared 
with the Nf WT (Figures 13 and 14). When one group is clearly less costly and more 
effective than the other, it is said to be dominant (Brazier et al. 2007). 
The CEAC was presented to estimate confidence intervals around ICERs to represent 
the uncertainty of cost-utility results. The CEAC represents the probability that an 
intervention (here, one waiting time group) is cost-effective at each value of willing­
ness to pay (WTP) for a QALY. Stochastic analysis by bootstrapping was applied to 
generate a distribution of costs and QALYs for both interventions. CEACs provided 
a graphical representation of the probability that a particular intervention was cost­
effective over a range of maximum WTP for a QALY value (Brazier et al. 2007). 
All analyses were carried out from the Finnish societal perspective, excluding produc­
tion losses and value-added taxes. While the longest observation period was less than 
two years, no discounting was applied. The data analyses were performed using SPSS 
versions 14 and 16 for Windows1 . 
1 SPSS Inc., Chicago, IL, USA 
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7.8 Ethical considerations 
Each patient provided a written informed consent. The study protocol was approved 
by the HUCH Surgery Ethics Committee (registration number 134/E6/02). Surgeons 
were unaware of the assigned intervention. For ethical reasons, double blinding was 
not possible. The trial was registered in the U.S. National Institutes of Health (NIH) 
ClinicalTrials.gov Register2 under trial number NCT00294424. 
2 See http://www.clinicaltrials.gov. 
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8 RESULTS
8.1 Effect of co-morbidity on HRQoL in patients waiting for total joint replacement (I)
The effect of co-morbidity was assessed as the difference in HRQoL between the 
patients (n = 893) with and without co-morbidity. Of the patients, 73% had one or 
more co-morbidities. At baseline, the mean 15D scores in patients with and without 
co-morbidity were 0.778 and 0.816, respectively. The difference in the score (Δ 0.038) 
was clinically important and statistically significant (p < 0.001). Of the dimensions 
related to OA, patients with co-morbidity scored lower on the dimensions of moving 
(Δ0.036, p < 0.001), vitality (Δ0.052, p < 0.001) and sexual activity (Δ0.051, p < 0.008). 
The deterioration of HRQoL was significantly associated with co-morbidity (Figure 6). 
Among knee patients, there were more patients with co-morbidities (79%) than among 
hip patients (67%) (p < 0.001).
The self-assessed health status of patients with co-morbidity, measured on a five-point 
scale, was worse than in the group without co-morbidity (p < 0.001). The effect of 
OA on the health-state deficiency as measured by VAS was 62% among patients with 
co-morbidity versus 76% (p < 0.001) among patients without co-morbidity.
In this analysis, severity of OA and co-morbidity were the main observational criteria 
of patients who were placed on the waiting list. In this analysis, we found that the 
HRQoL of all patients waiting for surgery was poor, but significantly worse in patients 
with co-morbidity. 
Figure 6. The 15D profiles (mean values) of patients with (Co-mo) and without co-morbidity (No Co-mo), at baseline.
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8.2 Characteristics of randomized groups in hip and knee patients and those who were lost 
to follow-up during the study (II, III) 
At baseline, after providing informed consent, 833 patients in three research hospitals
were randomly allocated to either the SWT (n = 346) or Nf WT (n = 487) group. Of 
the 833 randomized patients, 24 did not return the questionnaire at baseline, although
they had signed informed consent forms and had been randomized. The only available
information on these dropouts was gender and age. The mean age in dropouts was 
68 years in the SWT group (n = 12) and 72 years in the Nf WT group (n = 12); 75% of 
these were women. Of the remaining 809 patients, the mean age in both randomized 
groups was 66 years; and of these, 65% and 61% (respectively) were women. 
Of the patients, 162 (20%) dropped out after randomization at different stages of the 
follow-up for various reasons. Among these patients the mean age was 68 years and 
62% of these patients were women. The only statistically significant differences in the 
baseline characteristics between the dropouts and those who remained in the study 
to the end of follow-up were found in the mean age (dropouts slightly older) and in 
the proportion of living alone (slightly higher among dropouts). 
These lost to follow-ups were not included in the final analyses. The baseline char­
acteristics and comparison of the randomized groups and those who were lost to 
follow-up are presented in Table 6. 
At baseline in both hip and knee patients’ groups, the most significant 15D dimensions
affecting patients’ everyday life before TJR were moving, sleeping, vitality, discomfort
and symptoms, and sexual activity (Figure 7). 
Figure 7. The 15D profile of the hip and knee patients placed on the waiting list for TJR. 
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Table 6. Baseline characteristics in patients waiting for Total Joint Replacement and those lost to follow-up. 
Characteristics at baseline 
SWT 
n = 268 
NfWT 
n = 379 
Lost 
n = 162 P­value a P­value b 
Age, years (mean ± SD) 66 (9.5) 66 (9.7) 68 (9.9) 0.687 0.023* 
Females [n, (%)] 185 (65.1) 231 (60.5) 89 (62.2) 0.152 0.538 
Housing [n, (%)]
   Living alone 95 (33.9) 104 (28.1) 59 (41.3) 0.066 0.010* 
Basic education [n, (%)]
   Lover level 227 (81.1) 309 (83.3) 119 (83.8) 0.264 0.390 
Co-morbidity, yes [n, (%)] 207 (73.9) 270 (72.9) 108 (75.5) 0.406 0.330 
Medication to arthritis, yes [n, (%)] 248 (88.6) 329 (88.7) 124 (86.7) 0.531 0.302 
Medication to co-morbidity yes [n, (%)] 215 (76.8) 273 (73.6) 112 (78.3) 0.200 0.232 
Hip patients [n, (%)] 145 (51.1) 169 (47.1) 70 (41.3) 0.126 0.520
   HHS (mean ± SD)c 43.9 (13.5) 44.09 (14.4) 44.3 (12.9) 0.239 0.853 
Knee
   Pain score (mean ± SD)d 19.9(11.8) 20.9 (12.4) 19.96 (11.0) 0.355 0.030*
   Function score  (mean ± SD)e 48.4 (22.1) 46.9 (23.3) 52.4 (22.6) 0.567 0.171
   15D score (mean ± SD)f 0.765 (0.105) 0.774 (0.102) 0.761 (0.120) 0.222 0.360
   BMI (mean ± SD)g 28.8 (5.7) 28.7 (5.2) 27.7 (7.1) 0.809 0.099 
VAS (mean ± SD)h 67 (26) 65 (27) 62 (28) 0.540 0.089 
*p < 0.05.
 
a Dif ference between the randomized groups.
 
b Dif ference between the patients who remained in the study to the end of follow-up and those lost to follow-up.
 
c HHS (scale 0 = worst, 91 = best).
 
d KSS pain (score 0 = worst, 50 = best).
 
e K SS function (scale 0 = worst, 100 = best).
 
f 15D score ( scale 0 = worst, 1 = best).
 
g Body mass index (kg/m²).
 
h Visual Analog y Scale (0 to 100).
 
8.2.1 Waiting times in the randomized groups (II, III) 
There were statistically significant differences in mean waiting times between both 
randomized groups in hip and knee patients. The mean waiting time in the SWT 
hip patients was 74 (SD 145) days, and in Nf WT it was 194 (SD 175) days. Thus dif­
ference was 120 (95% CI, 93–143) days. Similarly in knee patients the mean waiting 
times for SWT and Nf WT groups were 95 (SD 81) and 239 (SD 135) days. Thus the 
difference was 144 (95% CI, 155–188) days, respectively. In both hip and knee groups 
there were patients in the SWT group who waited longer than three months. There 
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were also patients in both Nf WT groups (26 patients (10%) in the hip group and 18 
(7%) in the knee group) who were operated on within three months after having been 
placed on the waiting list. On the other hand, 71.2% in the SWT group were operated 
on within three months, and in the Nf WT group, 79 (22.3%) waited longer than one 
year. (Figure 8.) 
Figure 8. The distribution of waiting times in the randomized groups (Horizontally: 0 = NfWT, 1 = SWT, Vertically: 1 = 
hip, 2 = knee). 
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8.2.2 Effect of waiting time on health outcomes (II, III) 
The length of waiting time alone did not affect the health outcomes in both groups. 
The mean 15D score at admission in the hip patients’ SWT group was 0.768 and in 
the Nf WT group it was 0.769 (95% CI for mean difference: from −0.022 to 0.024). In 
knee patients, the mean 15D score at admission in the SWT group was 0.768 and in 
the Nf WT group it was 0.779 (95% CI for mean difference: from −0.020 to 0.029). 
(Figure 9.) 
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Figure 9. The mean 15D scores in the randomized hip and knee patients during the observation time.
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In hip patients, the mean self-reported HHS score in the SWT group was 42.99 and 
in the NfWT group it was 41.73 (95% CI for mean difference: from −5.233 to 1.816) 
(Figure 10). 
Figure 10. The mean Modified HHS during the whole observation period.
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The knee-specific pain and function scores were reported separately. At baseline, 
the mean pain score in the SWT patients was 18.93, and in the NfWT patients it was 
22.79 (95% CI for mean difference: from −1.478 to 3.969) and the mean function 
scores were 48.42 and 46.95 (95% CI for mean difference: from −6.659 to 3.493), 
respectively (Figure 11).
Figure 11. The mean Modified KSS (pain and function) during the whole observation period.
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During the waiting time there was no significant deterioration in the mean pain or 
function scores. There were improvements from admission to 12 months postopera-
tively in the mean 15D score and in the pain and function scores in all groups.
8.2.3 Costs of disease-specific medication (II, III)
The mean weekly costs of disease-specific medication (DSM) between the SWT and 
NfWT hip patients’ groups were EUR 5.56 and EUR 5.63, respectively. The total medi-
cation costs during the waiting time were significantly higher in the NfWT group. 
In knee patients, the mean costs of disease-specific medication during the waiting 
time in the SWT group were EUR 5.33 and in the NfWT group they were EUR 3.57 
in a week. The difference is statistically significant (p = 0.029). However, there was 
no statistically significant difference in the mean medication costs during the whole 
waiting time period. The mean total medication costs increased again during the 
year after TJR in both randomized groups, being highest in the knee patients’ NfWT 
group (EUR 143) (Figure 12).
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Figure 12. The mean total costs of disease-specific medication in the randomized groups from baseline to one year
postoperatively (H = hip, K = knee, SWT = short waiting time, NfWT = non fixed waiting time). 
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8.3 The cost-utility (IV) 
Due to dropouts, the final cost-utility analyses are based on 550 (66%) of the rand­
omized patients who completed all four questionnaires, with a mean (SD) age of 66 
(9.9; range; from 33 to 89) years, of which 345 (63%) were women and an additional 
243 (hip n = 130, knee n = 113) were in the SWT group and 307 (hip n = 149, knee 
n = 158) were in the Nf WT group (Table 6, p. 47). 
There were statistically significant differences in the knee patients’ mean 15D scores 
after the operation; those in the Nf WT group had better HRQoL. The 15D scores at 
each measurement point are presented in Table 7 (p. 52). 
In ITT analyses, the mean (SD) total costs of TJR among hip replacement patients 
were EUR 9,986 (3,540) in the SWT group and EUR 10,472 (4,686) in the Nf WT 
group, and EUR 9,809 (4,085) and EUR 9,801 (3116) among knee patients, respectively
(Table 8, p. 52). 
During the equally long follow-up period, the SWT hip patients experienced on aver­
age 1.341 QALYs and the Nf WT patients 1.327 QALYs. Furthermore, the SWT knee 
patients experienced on average 1.453 QALYs and the Nf WT patients 1.467 QALYs 
(Table 9, p. 53). 
In the ITT analyses of hip patients, the SWT group gained more QALYs at lower cost 
than patients in the Nf WT group. In knee patients, the results were opposite. However,
the difference in knee patients was insignificant. 
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Table 7. Mean 15D scores in hip and knee patients in the randomized groups. 
Measurement
point 
Hip Knee 
SWT 
n = 130 
NfWT
n = 149 
95% CI for
mean difference 
SWT 
n = 113 
NfWT 
n = 158 
95% CI for
mean difference 
At baseline 0.770 0.779 
−0.036 to 0.026 
0.772 0.779 
−0.004 to 0.030 
±SD (0.090) (0.100) (0.18) (0.12) 
At admission 0.772 0.771 
−0.023 to 0.021 
0.778 0.786 
−0.008 to 0.014 
±SD (0.090) (0.095) (0.105) (0.125) 
Three months pop 0.945 0.854 
−0.277 to 0.094 
0.811 0.842 
0.033 to 0.058* 
±SD (1.063) (0.105) (0.12) (0.11) 
One year pop 0.854 0.904 
−0.033 to 0.133 
0.823 0.852 
0.019 to 0.035* 
±SD (0.116) (0.503) (0.14) (0.10) 
*p < 0.01. 
Table 8. Mean costs of health care utilization; differences between the randomized groups in hip and knee patients. 
Measurement periods 
Hip Knee 
SWT
(n = 130) 
Mean 
costs (€) 
NfWT
(n = 149) 
Mean 
costs (€) 
95% CI 
for mean 
difference 
SWT
(n = 113) 
Mean 
costs (€) 
NfWT
(n = 158) 
Mean 
costs (€) 
95% CI 
for mean 
difference 
During the waiting time 441 422 
−236 to 198 
627 463 
−502 to 174 
±SD  (748) (1,081) (1491) (1,232) 
From admission to 3 
months postoperatively 8,015 8,274 −280 to 798 7,827 8,031 −168 to 576 
±SD  (2,288) (2,243) (1451) (1,613) 
From 3 months to 12 
months postoperatively 1,591 1,886 −477 to 1,068 1,561 1,309 −938 to 434 
±SD (2,405) (4,036) (3,121)  (2,344) 
Mean Total costs 9,986 10,472 
−486 to 1,458 
9,809 9,801 
−909 to 894 
±SD (3,540) (4,686) (4,085) (3,116) 
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Table 9. The results of cost-utility analyses of total joint replacement in hip and knee patients (ITT analyses). 
Incremental Incremental 
Cost costs Utility utility Cost­utility ICUR 
Strategy C (€) ΔC U (QALYs) ΔU C/U ΔC/ΔU 
SWT (hip) 9,986 1.3414 7,444.46 
NfWT (hip) 10,474 488 1.3265 −0.0149 7,895.97 32,751 
SWT (knee) 9,809 1.4528 6,751.79 
NfWT (knee) 9,802 −7 1.4669 0.0141 6,682.12 496 
8.3.1 Sensitivity analysis 
The point estimates in the ITT analysis above thus suggest strong dominance for SWT 
among hip patients. On the basis of probabilistic sensitivity analyses in hip patients, 
the 95% CI for mean difference in QALYs was from −0.048 to 0.076 and in costs from 
EUR −1,453 to EUR 464. In knee patients, the 95% CI for mean difference in QALYs 
was from −0.095 to 0.063, and in costs from EUR −913 to EUR 955 (Figures 13 and 14). 
Figure 13. Cost-effectiveness plane in hip replacement (diamond stands for the base case result). In 59.5% of 
simulated cases, SWT was both less costly and more effective (quadrant IV); in 25.4% less costly and less effective 
(quadrant III); in 10.5% more costly and more effective (quadrant II); in 4.6% more costly and less effective 
(quadrant I). 
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Figure 14. Cost-effectiveness plane in knee replacement (diamond stands for the base case result). In 17.5% of 
simulated cases, SWT was both less costly and more effective (quadrant IV); in 31.7% less costly and less effective 
(quadrant III); in 16.8% more costly and more effective (quadrant II); in 34.0% more costly and less effective 
(quadrant I). 
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If the willingness to pay for a QALY is EUR 20,000, the probability of SWT being 
cost-effective is about 85% in hip patients and about 40% in knee patients (Figure 15). 
Figure 15. Cost-effectiveness acceptability curves for the short waiting time in hip and knee replacement. 
Probability of being cost-effective 
1.0 
0.9 Hip  
0.8 
0.7 
0.6 
0.5 
0.4 Knee  
0.3 
0.2 
0.1 
0.0 
0 10,000 20,000 30,000 40,000 50,000 
Willingness to pay for a QALY, $ 
The effect of waiting time on health outcomes and costs of total joint replacement in hip and knee patients
 
 
 
   
  
55 
Because there were patients in both randomized groups who did not follow the main 
protocol, we carried out a secondary per-protocol analysis. As a result, the mean total 
cost among hip patients was EUR 10,302 (±3788) in the SWT group and EUR 10,402 
(±4854) in the Nf WT group, and EUR 9,374 (±3,259) and EUR 9,904 (±3,115) among 
knee patients, respectively. During the equally long follow-up period, the SWT hip 
patients experienced, on average, 1.3536 QALYs and the Nf WT patients 1.3879 QALYs.
Correspondingly, the SWT knee patients experienced, on average, 1.4428 QALYs and 
the Nf WT patients 1.5022 QALYs. Point estimates thus suggest an ICUR of EUR 2,941
for Nf WT among hip patients and of EUR 8,983 among knee patients. This analysis 
seemed to add to the uncertainty over whether the difference in waiting time actually 
makes much difference in terms of cost-utility (Table 10). 
Table 10. Per-protocol analysis of cost-utility of Total Joint Replacement in hip and knee patients. 
Strategy 
Costs 
C (€) 
Incremental 
costs 
ΔC 
Utility 
(QALYs) 
Incremental 
utility
ΔQALYS 
Cost­utility
C/QALYs
ICUR 
ΔC/ΔQALYs 
Hip(SWT) 10,302 1,354 7,608.57 
Hip (NfWT) 10,402 −100 1,388 −0.034 7,494.24 2,941 
Knee (SWT) 9,374 1,443 6,496.19 
Knee (NfWT) 9,904 −530 1,502 −0.059 6,593.87 8,983 
According to the present study, there does not seem to be a significant difference in 
the cost-utility of short and longer waiting times for TJR, at least given the waiting 
time difference between our study groups. 
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9 DISCUSSION 
Osteoarthritis is the most common cause of musculoskeletal disability and pain in 
the world. Furthermore, as a result of the prevalence of OA, the number of patients 
on waiting lists and the waiting times for elective total joint replacements are increas­
ing. There are studies that have evaluated the effect of waiting time on HRQoL and 
other outcomes of TJR, but few of these have evaluated the effect of waiting time on 
these outcomes in two different waiting time groups. The main aim of the present 
study was to evaluate the effect of different lengths of waiting time on HRQoL and 
other health outcomes before and after TJR. In the study, patients were randomized 
into short and non-fixed waiting time groups and followed on the basis of the ITT 
principle. This study was conducted during the time period when waiting times for 
elective surgery were long and the share of patients having waited for over 6 months 
of all operated patients were highest in knee replacements (41%) and in hip replace­
ments (32%) (Mikkola et al. 2008). 
9.1 HRQoL in patients waiting for Total Joint Replacement 
According to earlier studies, patients waiting for total joint replacement have poor 
quality of life and progressive pain and reduction in physical functioning (Derrett 
et al. 1999; Kelly et al. 2001; Croft et al. 2002; Ackerman et al. 2005; Hirvonen et al. 
2006; McHugh et al. 2008). However, a systematic review of the impact of waiting time
for TJR on pain and functional status concluded that there was strong evidence that 
pain (in hip and knee OA) and self-reported functioning (in hip OA) did not deterio­
rate during a waiting time less than 180 days (Hoogeboom et al. 2009). The impact 
of waiting time was mostly seen as deterioration in disease-specific measurements. 
According to Hoogeboom et al. (2009), there is conflicting evidence for change in 
self-rated functioning in patients with knee OA, and indefinite results were reported 
for long waiting times (> 6 months), though pain might increase in hip OA patients. 
In our study, the mean total scores of HRQoL instruments did not deteriorate while 
waiting. Furthermore, the mean modified KS score in the Nf WT group was better at 
admission than at baseline. These findings are in line with earlier studies. However, 
some studies have shown opposite findings. For example Bachrach-Lindström et al. 
(2008), found that a long waiting time (> 6 months) is detrimental to patients’ HRQoL,
causing pain, reduced functional condition, and an increased need for support from 
relatives, thus limiting independence in daily life (Bachrach-Lindström et al. 2008). 
Why did the HRQoL not deteriorate during the waiting time? One explanation might 
be that when patients are placed on the waiting list, the awareness of upcoming surgery
might bring psychological relief, and at the same time, pain and functional ability 
are managed with appropriate medication during the waiting time. This was seen as 
an increasing use of DSM during the waiting time in all patient groups. According 
to  Conner-Spady et al. (2007) patients’ view of waiting times are not only related to 
quality of life, but also to prior expectations and notions of fairness and priority. Ac­
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cording to earlier literature reviews, no other studies have been published in which the
waiting time effect was tested by randomizing the patients into two different waiting 
time groups at baseline. 
9.2 Baseline co-morbidity and HRQoL 
In Finland, 44% of the working population and 82% of senior citizens have at least
one chronic disease. Some studies have suggested that the use of a generic HRQoL
instrument in the studies of OA, where co-morbidity is common, would be useful in
characterizing the global burden of this disease (Piccorillo 2000; Salaffi et al. 2005).
The findings of the present study have shown that OA patients with co-morbidity have
poorer HRQoL than patients without co-morbidity. However, those patients without
co-morbidity seem to rate their burden of OA, when measured by VAS, even higher
than OA patients with co-morbidity before surgery. Assessing the co-morbidity con­
dition and HRQoL at baseline or even earlier in time, when patients are waiting with
a referral for access to a waiting list, the severity of co-morbidity might operate as an
instrument to help in prioritization in medical decision-making for health care delivery. 
9.3 Randomization and waiting time 
This study is the first clinical trial where patients were randomly allocated to different 
waiting time groups when placed on the waiting list for elective surgery. Randomi­
zation was based on a flowchart of four phases: enrolment, intervention allocation,
follow-up, and data analysis of a parallel randomized trial of two groups modified 
from the CONSORT Statement 2010 (Schulz and Grimes 2002). The patients were 
randomized to different waiting time groups (SWT and NfWT) at baseline and were 
followed according to the ITT principle. The patients awaiting TJR were prospectively 
followed from the time of being placed on the waiting list to admission, with waiting 
time recorded precisely, and further for a year postoperatively, providing evidence of the
effect of waiting time on pre- and postoperative health status. Randomization was suc­
cessfully completed, and the groups did not differ from each other at baseline. Further,
the sample size estimate was based on the primary outcome variable, the 15D score. 
9.4 Health outcome measures and costs of osteoarthritis 
Both generic and disease-specific instruments were used. The generic 15D has been 
used successfully in earlier studies dealing with hip and knee replacement and thus 
facilitates a comparison of the pre-surgery scores in these studies (Rissanen et al. 
1995, 1996 and 1997; Räsänen et al. 2005, 2006 and 2007). Earlier research has shown 
that in most of the important properties (reliability, content validity, sensitivity in 
terms of discriminatory power, and responsiveness to change), the 15D instrument 
compares at least equally with other similar instruments that produce a valuation­
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based single index number. And recent research has since confirmed that, especially 
in the rehabilitation of musculoskeletal disorders, the 15D instrument was at least as 
responsive as the SF-6D and much more responsive than the EQ-5D. Furthermore, 
the scores of 15D are suitable for QALY calculation. Both HHS in hip patients and 
KSS in knee patients are well-known, standardized and widely used disease-specific 
instruments to measure both pain and functioning in OA patients. We used these 
instruments as modified. In an earlier study by Mahomed et al. (2001), a compari­
son between self-report HHS and surgeon-assessed HHS was made. They concluded 
that the measurements showed excellent concordance and supported the use of self­
reported HHS (Mahomed et al. 2001). The disease-specific, self-reported modified 
KSS was used to measure only knee pain and physical function, and it has been found 
to be responsive to these changes in the study by Lingard et al. (2001). 
The utilization and costs of health care and social services were surprisingly low during
the whole observation period, which is against common assumptions, though there 
is some scientific evidence concerning costs related to OA during the waiting time. 
According to the study of Quan et al. (2002), waiting for a surgery may have an inde­
pendent economic effect. If a delay for surgery equates with failed problem resolution,
then it is reasonable to presume that additional health services will be required until 
the definitive surgical service is performed and it may increase overall health service 
expenditures. However, Quan et al. (2002) concluded that no evidence was found to 
suggest that waiting for common surgical procedures is correlated with higher health 
service expenditures pre- or postoperatively. They found that waiting time is not a 
proxy for health service use and health service costs do not decrease markedly after 
surgery (Quan et al. 2002). Our findings support these results, as patients with OA 
did not use health care services significantly more than the general population of the 
same age. However, Fielden et al. (2005) suggested that longer waits (> 5 months) incur
higher economic costs while waiting, and March et al. (2002) found that poorer pre­
surgery health status predicts higher expenditures during the first postoperative year. 
Some uncertainty was embedded in the results of utilization and costs of health care 
and social services. There might be several reasons for this. Firstly, the questionnaire 
was self-reported and the questions were presented three months retrospectively.
Secondly, elderly people may under- or overestimate the utilization; the data showed 
that the responses were partly incomplete, and some patients answered that they had 
utilized services but did not mention the number of visits or what kind of services were
used. Thirdly, we evaluated only the services and costs related to OA. These things 
might lead to underestimation of health care and social services. 
In the present study, the mean length of a hospital stay was 2 days for hip patients and 
3 days for knee patients. According to the TJR statistics, in Finland the mean costs of 
surgery between the years 2002 and 2003 was EUR 7,421 and costs including hospital 
days were EUR 7,643: EUR 7,462 for hip patients and EUR 7,729 for knee patients 
(Remes et al. 2007). In this study the costs of surgery were drawn from the Finnish 
Hospital Discharge Register (FHDR); the mean cost for THR was EUR 7,852, and for 
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TKR it was EUR 7,655. The other costs related to OA were calculated by multiplying 
the Finnish unit costs by the amount of service use as reported by patients. 
9.5 Cost-utility of Total Joint Replacement 
Earlier non-randomized studies have found that total joint replacements of hip and 
knee are effective and cost-effective interventions (Bourne 1996; Rissanen et al. 1997; 
Segal et al. 2004; Räsänen et al. 2006; Navarro Espigares and Torres 2008; Xie et al. 2010;
Higashi and Barendregt 2011). However, according to several studies, knee patients 
gain more QALYs at lower cost than hip patients (Segal et al. 2004; Navarro Espigares 
and Torres 2008). These findings are partly opposite to ours. According to the results 
of the ITT analyses of this randomized study, a waiting time ≤ 3 months might have 
a positive effect on the cost-utility of THR. But in knee patients, no evidence was 
found that patients in SWT would benefit more than those waiting over 3 months. 
9.6 Limitations of the study 
Dropout is a potential weakness of an RCT; that was also the case in this study. Firstly,
235 of the eligible patients refused to participate in the study and 162 were lost in the 
follow-up during the study. We tested whether those (n = 162) who dropped out after 
randomization at any stage of the follow-up differed in the baseline characteristics 
from those who remained in the study to the very end. The only statistically significant
differences were found in the mean age (dropouts slightly older) and in the proportion
of living alone (among dropouts slightly higher). Secondly, 126 patients in the SWT 
group waited more than three months; and there were patients in the Nf WT group 
who were operated within three months after having been placed on the waiting list. 
However, the primary analysis was based on the ITT principle to avoid bias associ­
ated with a non-random loss of participants. In addition, per-protocol analyses were 
performed as supplementary analyses. In the SWT group, those compliant with the 
allocated waiting time of three months (and all of the patients in the Nf WT group 
were included in the analysis) supported the main findings and did not show a sta­
tistically or clinically important difference in HRQoL between randomized groups. 
Thirdly, establishing comparable QALYs and costs between the SWT and Nf WT groups
did include challenges. As a solution, the mean follow-up time was set the same in 
both groups. However, we do not know exactly how the HRQoL (and costs) in the 
SWT group developed during the time from the last measurement in that group to the
final measurement in the Nf WT group. The HRQoL may have deteriorated slightly 
due to ageing or co-morbidity. But because the mean time difference between the last 
measurements in the groups was only 4–8 months, the change would probably be 
negligible, and therefore our assumption of no change may be justified. On the other 
hand, had the SWT group incurred further costs contrary to our assumption, its total
cost would have been underestimated. As these changes would probably be marginal, 
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they might not have affected our conclusions. However, there is a lot of variance around
the point estimates, and the differences in costs and QALYs between the per-protocol 
groups were not statistically significant in hip or knee patients. 
Furthermore, data on medication were obtained from patients’ self-reports, and there
was no distinction between self-care and prescription medication. For temporary 
medication, we used mean dosages. Due to these factors, the differences between the 
randomized groups may have been underestimated. 
9.7 Reliability and validity of the study 
In this study, we focused on OA of the hip and knee joint, which is the most common 
cause of musculoskeletal disability and pain in the world. It is a chronic disease affect­
ing patients’ quality of life, and its incidence and prevalence will increase in the future
due to the ageing of the population. This might lead to increasing volumes of TJR and 
further lengthening of waiting times. A randomized controlled trial (RCT) is a type of
scientific experiment commonly used in testing the efficacy or effectiveness of health 
care services or health care technologies. For health care interventions such as new 
therapies or pharmaceuticals, many countries have formal requirements for provision
of safety and efficacy data prior to product licensing Schulz and Grimes 2002). RCTs
are not common in surgery; however, we successfully completed the procedure to 
randomize patients into two different waiting time groups. All eligible patients had a 
chance to be recruited to the study and had the possibility to be allocated to the SWT 
group. We did not change the hospitals’ routine procedure. 
As far as HRQoL is concerned, we cannot be sure that there was no change in extrane­
ous influences that might have occurred, such as an attitude change over time. This 
could lead to a difference in the responses provided. When a respondent answers a set 
of test items, the score obtained represents only a limited sample of behaviour (Crocker
and Algina 1986). As a result, the scores may change due to some characteristic of the 
respondent, which may lead to errors of measurement. These kinds of errors will reduce
the accuracy and consistency of the instrument and test scores (Golafshani 2003). 
In this study, both generic and disease-specific instruments we used are referred to 
as stable and validated. If we are dealing with a repeatable measure, then the results 
should be similar in consecutive measurements if no change in the variable to be 
measured has occurred. In this study, the data were collected from four different hos­
pitals, and the data collection was repeated four times during the study. This study 
was conducted during the time when the waiting times for elective surgery were long 
and the New Healthcare Reform was introduced in Finland. According to the reform,
elective surgery must be provided within three months or at least within six months.
The results of this study seem to suggest that longer waiting times, at least as long as 
those experienced in this study, do not affect HRQoL or other health outcomes related
to TJR in hip and knee patients. 
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10 CONCLUSIONS AND SUGGESTIONS FOR FURTHER STUDIES 
On the basis of the present study, the following conclusions can be drawn: 
1) It is possible to perform randomization in a clinical trial, where patients are
placed on a waiting list for a non-urgent surgical procedure. In this study, each 
patient had an equal possibility to be assigned by chance, rather than by choice,
either to the short waiting time group or to the non-fixed waiting time group. 
2) When patients are placed on the waiting list for TJR, they have deteriorated
HRQoL, and the length of the waiting time, at least as experienced in this study,
does not have a significant effect on HRQoL during the waiting time. 
3) We do not have an accurate or credible answer to the question of an optimal length
of the waiting time. According to the present study, the length of waiting time did
not alone affect the cost-utility of the TJR, the severity of pain, or deterioration 
in functioning. 
4) Understanding patients’ views on waiting for surgery has implications for better 
management of waiting times for TJR. When implementing waiting time reform,
health authorities need instruments for decision-making on optimizing the
waiting times. Rapid access to care is not always related to better outcomes of
the intervention, and consequently, the length of the waiting time should not 
categorically be the same for each patient. 
5) Both generic and disease-specific outcome measures are needed to evaluate
outcomes of before and after surgery in different patient groups. 
6) Co-morbidity affects OA patients’ HRQoL already when placed on the waiting list,
and co-morbidity should be considered when the decision about surgery is made.
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APPENDICES 
QUALIT Y OF LIFE QUESTIONNAIRE (15D©) 
Please read through all the alternative responses to each question before placing 
a cross (x) against the alternative that best describes your present health status.
Continue through all 15 questions in this manner, giving only one answer to each.
QUESTION 1. MOBILITY 
1 ( ) I am able to walk normally (without difficulty) indoors, outdoors and on stairs.
2 ( ) I am able to walk without difficulty indoors, but outdoors and/or on stairs I have 
        slight difficulties.
3 ( ) I am able to walk without help indoors (with or without an appliance), but 
        outdoors and/or on stairs only with considerable difficulty or with help from 
        others.
4 ( ) I am able to walk indoors only with help from others.
5 ( ) I am completely bed-ridden and unable to move about.
QUESTION 2. VISION 
1 ( ) I see normally, i.e. I can read newspapers and TV text without difficulty (with or 
        without glasses).
2 ( ) I can read papers and/or TV text with slight difficulty (with or without glasses).
3 ( ) I can read papers and/or TV text with considerable difficulty (with or without 
        glasses).
4 ( ) I cannot read papers or TV text either with glasses or without, but I can see enough
        to walk about without guidance.
5 ( ) I cannot see enough to walk about without a guide, i.e. I am almost or completely 
        blind.
QUESTION 3. HEARING 
1 ( ) I can hear normally, i.e. normal speech (with or without a hearing aid).
2 ( ) I hear normal speech with a little difficulty.
3 ( ) I hear normal speech with considerable difficulty; in conversation I need voices to 
        be louder than normal.
4 ( ) I hear even loud voices poorly; I am almost deaf.
5 ( ) I am completely deaf.
QUESTION 4. BREATHING 
1 ( ) I am able to breathe normally, i.e. with no shortness of breath or other breathing 
        difficulty.
2 ( ) I have shortness of breath during heavy work or sports, or when walking briskly on
        flat ground or slightly uphill.
3 ( ) I have shortness of breath when walking on flat ground at the same speed as others 
        my age.
4 ( ) I get shortness of breath even after light activity, e.g. washing or dressing myself.
5 ( ) I have breathing difficulties almost all the time, even when resting.
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QUESTION 5. SLEEPING 
1 ( ) I am able to sleep normally, i.e. I have no problems with sleeping.
2 ( ) I have slight problems with sleeping, e.g. difficulty in falling asleep, or sometimes 
        waking at night.
3 ( ) I have moderate problems with sleeping, e.g. disturbed sleep, or feeling I have not 
        slept enough.
4 ( ) I have great problems with sleeping, e.g. having to use sleeping pills often or 
        routinely, or usually waking at night and/or too early in the morning.
5 ( ) I suffer severe sleeplessness, e.g. sleep is almost impossible, even with full use of
        sleeping pills or staying awake most of the night.
QUESTION 6. EATING 
1 ( ) I am able to eat normally, i.e. with no help from others.
2 ( ) I am able to eat by myself with minor difficulty (e.g. slowly, clumsily, shakily, or 
        with special appliances).
3 ( ) I need some help from another person in eating.
4 ( ) I am unable to eat by myself at all, so I must be fed by another person.
5 ( ) I am unable to eat at all, so I am fed either by tube or intravenously.
QUESTION 7. SPEECH 
1 ( ) I am able to speak normally, i.e. clearly, audibly and fluently.
2 ( ) I have slight speech difficulties, e.g. occasional fumbling for words, mumbling, or 
        changes of pitch.
3 ( ) I can make myself understood, but my speech is disjointed, faltering, stuttering or 
        stammering.
4 ( ) Most people have great difficulty understanding my speech.
5 ( ) I can only make myself understood by gestures.
QUESTION 8. EXCRETION 
1 ( ) My bladder and bowel work normally and without problems.
2 ( ) I have slight problems with my bladder and/or bowel function, e.g. difficulties with 
        urination, or loose or hard bowels.
3 ( ) I have marked problems with my bladder and/or bowel function, e.g. occasional 
‘accidents’, or severe constipation or diarrhoea.
4 ( ) I have serious problems with my bladder and/or bowel function, e.g. routine 
‘accidents’, or need of catheterization or enemas.
5 ( ) I have no control over my bladder and/or bowel function.
QUESTION 9. USUAL ACTIVITIES 
1 ( ) I am able to perform my usual activities (e.g. employment, studying, housework,
         free-time activities) without difficulty.
2 ( ) I am able to perform my usual activities slightly less effectively or with minor 
        difficulty.
3 ( ) I am able to perform my usual activities much less effectively, with considerable 
        difficulty, or not completely.
4 ( ) I can only manage a small proportion of my previously usual activities.
5 ( ) I am unable to manage any of my previously usual activities.
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QUESTION 10. MENTAL FUNCTION 
1 ( ) I am able to think clearly and logically, and my memory functions well.
2 ( ) I have slight difficulties in thinking clearly and logically, or my memory sometimes 
fails me.
3 ( ) I have marked difficulties in thinking clearly and logically, or my memory is 
        somewhat impaired.
4 ( ) I have great difficulties in thinking clearly and logically, or my memory is seriously 
         impaired.
5 ( ) I am permanently confused and disoriented in place and time.
QUESTION 11. DISCOMFORT AND SYMPTOMS 
1 ( ) I have no physical discomfort or symptoms, e.g. pain, ache, nausea, itching, etc.
2 ( ) I have mild physical discomfort or symptoms, e.g. pain, ache, nausea, itching, etc.
3 ( ) I have marked physical discomfort or symptoms, e.g. pain, ache, nausea, itching, etc.
4 ( ) I have severe physical discomfort or symptoms, e.g. pain, ache, nausea, itching, etc.
5 ( ) I have unbearable physical discomfort or symptoms, e.g. pain, ache, nausea,
         itching, etc.
QUESTION 12. DEPRESSION 
1 ( ) I do not feel at all sad, melancholic or depressed.
2 ( ) I feel slightly sad, melancholic or depressed.
3 ( ) I feel moderately sad, melancholic or depressed.
4 ( ) I feel very sad, melancholic or depressed.
5 ( ) I feel extremely sad, melancholic or depressed.
QUESTION 13. DISTRESS 
1 ( ) I do not feel at all anxious, stressed or nervous.
2 ( ) I feel slightly anxious, stressed or nervous.
3 ( ) I feel moderately anxious, stressed or nervous.
4 ( ) I feel very anxious, stressed or nervous.
5 ( ) I feel extremely anxious, stressed or nervous.
QUESTION 14. VITALITY 
1 ( ) I feel healthy and energetic.
 
2 ( ) I feel slightly weary, tired or feeble.
 
3 ( ) I feel moderately weary, tired or feeble.
 
4 ( ) I feel very weary, tired or feeble, almost exhausted.
 
5 ( ) I feel extremely weary, tired or feeble, totally exhausted.
 
QUESTION 15. SEXUAL ACTIVITY 
1 ( ) My state of health has no adverse effect on my sexual activity.
2 ( ) My state of health has a slight effect on my sexual activity.
3 ( ) My state of health has a considerable effect on my sexual activity.
4 ( ) My state of health makes sexual activity almost impossible.
5 ( ) My state of health makes sexual activity impossible. 
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MODIFIED DISEASE-SPECIFIC MEASURES 
Hip patients Knee patients 
Item Description Points Item Description Points 
Pain 1 None 44 Pain 1 None 50 
2 Slight, occasional 40 2 Mild and occasional 45 
3 Mild pain, rarely with unusual 
activities 
30 3 Mild, stairs only 40 
4 Moderate pain, some limitation of
ordinary activities 
20 4 Mild, walking and stairs 40 
5 Marked pain, limitation of activities 10 5 Moderate, occasional 20 
6 Totally disable, pain in bed 0 6 Moderate, continual 10 
7 Severe 0 
Function (Gait) Function 
1. Limp 1 None 11 1. Walking 1 > 1.5 km / unlimited 50 
2 Slight 8 2 1–1.5 km 40 
3 Moderate 5 3 100–500 m 20 
4 Severe 0 4 Indoors only 10 
2. Support 1 None 11 5 Unable 0 
2 Cane for long walks 7 2. Stairs 1 Normal, up and down 50 
3 Cane most of the time 5 2 Normal up, down with rail 40 
4 One crutch 3 3 Up and down with rail 30 
5 Two canes 2 4 Up with rail, unable down 15 
6 Two crutches 0 5 Unable 0 
7 Not able to walk 0 
3. Distance walked 1 > 1.5km / unlimited 11 
2 1–1.5 km 8 
3 100–500 km 5 
4 Indoors only 2 
5 Unable 0 
Function (Activities) 
1. Stairs 1 Normally 4 
2 Normally, using a railing 2 
3 Step by step, using a railing 1 
4 Unable to do stairs 0 
2. Shoes and socks 1 With ease 4 
2 With difficulty 3 
3 Unable 0 
3. Sitting 1 In ordinary chair one hour 5 
2 On a higher chair for one hour 3 
3 Unable to sit 0 

ORIGINAL PUBLICATIONS
 

  
 
  
I 
Tuominen U, Blom M, Hirvonen J, Hietaniemi K, Lehto MUK, Paavolainen
P, Seitsalo S, Sintonen H, Rissanen P. Effects of comorbidities to health­
related quality of life in patients awaiting major joint replacement.
Health and Quality of Life Outcomes 2007; 5: 16; doi:10.1186/1477­
7525­5­16.
I 

   
  
    
   
  
 
  
 
    
 
   
   
  
 
  
 
 
 
Health and Quality of Life Outcomes
 
BioMedCentral 
Research Open Access 
The effect of co-morbidities on health-related quality of life in 
patients placed on the waiting list for total joint replacement 
Ulla Tuominen*1,2, Marja Blom3,4, Johanna Hirvonen2, Seppo Seitsalo5, 
Matti Lehto6, Pekka Paavolainen5, Kalevi Hietanieni3, Pekka Rissanen7 and 
Harri Sintonen2 
Address: 1National Research and Development Centre for Welfare and Health, Helsinki, Finland, 2University of Helsinki, Finland, 3HUCH 
Hospital Area, Espoo, Finland, 4Academy of Finland, 5Orton Orthopaedic Hospital, Helsinki, Finland, 6Coxa, Hospital for Joint Replacement, 
Medical Research Fund of Tampere University Hospital, Tampere, Finland and 7University of Tampere, Finland 
Email: Ulla Tuominen* - ulla.tuominen@stakes.fi; Marja Blom - marja.blom@hus.fi; Johanna Hirvonen - johanna.hirvonen@mikkeliamk.fi;
Seppo Seitsalo - seppo.seitsalo@invalidisaatio.fi; Matti Lehto - matti.lehto@pshp.fi; Pekka Paavolainen - pekka.paavolainen@invalidisaatio.fi;
Kalevi Hietanieni - kalevi.hietaniemi@hus.fi; Pekka Rissanen - pekka.rissanen@uta.fi; Harri Sintonen - harri.sintonen@helsinki.fi 
* Corresponding author  
Published: 15 March 2007 Received: 5 February 2007 
Health and Quality of Life Outcomes 2007, 5:16 doi:10.1186/1477-7525-5-16 
Accepted: 15 March 2007 
This article is available from: http://www.hqlo.com/content/5/1/16
 
© 2007 Tuominen et al; licensee BioMed Central Ltd. 

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 

which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 
Abstract 
Background: Co-morbidity is a powerful predictor of health care outcomes and costs, as well as an 
important cofounder in epidemiologic studies. The effect of co-morbidities is generally related to mortality 
or complications. This study evaluated the association between co-morbidity and health-related quality of 
life (HRQoL) in patients awaiting total joint replacement. 
Methods: A total of 893 patients were recruited to the study between August 2002 and November 2003 
in four Finnish hospitals. The effect of co-morbidity on HRQoL was measured by the generic 15D 
instrument and by a Visual Analog Scale (VAS). Comparative variance analysis of socio-demographic and 
clinical characteristics was described by using either an independent samples t-test or the Chi-square test. 
The differences in each of the 15D dimensions and the overall 15D single index score for patients were 
calculated. Two-sided p-values were calculated with the Levene Test for Equality of Variances. 
Results: Patients with co-morbidity totaled 649; the incidence of co-morbidity was 73%. The mean 
number of co-morbidities among the patients was two. At baseline the 15D score in patients with and 
without co-morbidity was 0.778 vs 0.816, respectively. The difference of the score (0.038) was clinically 
and statistically significant (P < 0.001). The patients' scores with and without co-morbidity on the different 
15D dimensions related to osteoarthritis-moving, sleeping, usual activities, discomfort and symptoms, 
vitality and sexual activity–were low in both groups. Patients with co-morbidity scored lower on the 
dimensions of moving, vitality and sexual activity compared to the patients without co-morbidity. Co­
morbidity was significantly associated with a reduced HRQoL. Patients without co-morbidity had poorer 
VAS, arthritis had strong effect to their quality of life compared to the patients with co-morbidity. 
Conclusion: Assessing co-morbidity in patients placed on the waiting list for joint replacement may be 
useful method to prioritization in medical decision-making for healthcare delivery. The assessment of co­
morbidities during waiting time is important as well as evaluating how the co-morbidity may affect the final 
outcomes of the total joint replacement. 
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Background 
Chronic diseases have been shown to negatively affect 
people's quality of life (QoL), and they are a common rea­
son for disability and early death. According to the Finn­
ish National Health 2000 Survey half of the Finnish 
population aged over 30 has at least one chronic disease, 
while 44 % of the working population and 82 % of senior 
citizens have at least one chronic disease [1]. The decline 
of the populations' self-reported sense of well-being is a 
consequence of ageing, with no observable difference 
between women and men. The commonest chronic dis­
eases in Finland are: cardiovascular disease, musculoskel­
etal disease, diabetes, and lung diseases [1]. 
Co-morbid or coexisting disease refers to the occurrence 
of two or more diseases in the same individual. The pres­
ence of co-morbidity has a pervasive effect on QoL, 
research, and clinical practice through its influence on 
diagnosis, prognosis, treatment and, health care delivery. 
Each co-morbid disease may have its own effect on QoL 
while also having a clinical effect on patients' sense of 
well-being. It is also important for studies of patients with 
chronic disease in whom mortality is rare and the goal of 
medical care is to control the course of the disease and 
maximize the quality of life [2]. Evaluations on how dif­
ferent diseases affect patients' health-related quality of life 
(HRQoL) focus mostly on the index disease, considering 
the effect of co-morbidities to a lesser extent. However 
when the focus is on the consequences–mortality, compli­
cations or in the costs of the medical care – co-morbidity 
becomes an important denominator. 
Co-morbidity can also play an important role in different 
types of studies. Randomized controlled trials and prog­
nostic studies might be complicated by co-morbidity. It 
can either act as a cofounder, threatening the internal 
validity, or as an effect modifier, threatening the internal 
and external validity of the study: therefore an efficient 
method is needed to measure co-morbidity [3]. 
In Finland, total joint replacements (TJR) are surgical pro­
cedures with high volume and long waiting times. In 
2003, primary hip and knee replacements were carried out 
for almost 15500 patients [4]. For patients with primary 
total joint replacement of hip the median waiting time 
was 155 days, and for patients with primary total joint 
replacement of knee, 205 days [4]. One reason for these 
long waiting times is that OA is not itself life threatening. 
However, some previous studies have reported that those 
awaiting hip or knee replacement have a significantly 
poorer quality of life and that arthritis becomes a chronic 
and heavy burden to the patients [5,6]. Also few studies 
having examined waiting time effects on health status in 
OA patients have not been able to show that patients hav­
ing to wait longer would suffer from pain and functional 
http://www.hqlo.com/content/5/1/16 
difficulties or poorer HRQoL than those with shorter wait­
ing [7,8]. 
In 2002, a prospective multi-centre study was started in 
four Finnish hospitals. The aim of this larger study is to 
assess the effect, the costs and the cost effectiveness of the 
waiting time in patients awaiting TJR. This report is part of 
this ongoing study. The objective of this paper is to evalu­
ate the effect of co-morbidity on HRQoL in OA patients 
when placed on the waiting list for TJR. 
Methods 
Data collection 
Between August 2002 and November 2003, a total of 893 
OA patients were enrolled in the study in four Finnish 
hospitals: the Helsinki University Central Hospital: Surgi­
cal Hospital, the Helsinki University Central Hospital: 
Jorvi Hospital, the Coxa Hospital for Joint Replacement 
and the Orton Orthopedic Hospital. Patients were 
recruited into the study through contact with orthopedic 
and practice staff. 
The key inclusion criteria were a need for a primary TJR 
due to OA of the hip or knee joint as evaluated by the hos­
pital surgeon; patient was aged 16 or older and placed on 
the waiting list in a research hospital, and the patient was 
willing and mentally able to participate in the study. The 
key exclusion criteria were patients with rheumatoid 
arthritis, congenital hemophilia or congenital deformi­
ties, and fractures. Patients completed a self-administered 
questionnaire when placed on the waiting list for TJR. The 
questionnaires were distributed to the patients at the hos­
pital and were returned by post. Common guidelines for 
administering the questionnaires were provided at each 
hospital. The patients completed a socio-demographic 
form, reported their co-morbidities as diagnosed by a 
medical doctor, completed the visual analog scale (VAS), 
and also completed separate questionnaires for self­
reported sense of well-being and HRQoL. Each patient 
provided informed consent. The study was approved by 
the Helsinki University Central Hospital Surgery Ethics 
Committee. 
In this study, the co-morbidity data was collected from the 
patients' reported co-morbidities as diagnosed by a medi­
cal doctor. The patients were assigned to subgroups 
according to co-morbidity status. The patients' reported 
diseases were classified according to the ICD10 [9], giving 
nine diagnoses groups in total: tumors, diabetes mellitus, 
respiratory disease, cardiovascular disease, high choles­
terol, mental health problems, muskuloskeletal system 
diseases, endocrinological problems, and visual or hear­
ing problems. 
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Co-morbidity and Quality of Life 
It is difficult to choose the most appropriate co-morbidity 
measurement because comparative data on how the avail­
able instruments perform in different disease settings are 
limited [10,11]. There are several reports about different 
measurements and measurement combinations for 
assessing co-morbidity. Instruments used in clinical 
research to calculate co-morbidity include, for example, 
the Carlson Index [13], the Cumulative Illness Rating 
Scale (CIRS) [14], the Index of Coexistent Diseases 
(ICED) [15] and the Kaplan Index [16]. Both generic and 
disease-specific QoL instruments are used to assess the 
effect of co-morbidities in clinical trials [12,17]. 
In this study the effect of co-morbidity was assessed as the 
difference in HRQoL between the patients with and those 
without co-morbidity. HRQoL was measured by using the 
generic, multidimensional, standardized, and self-admin­
istered 15D instrument. The 15D is a Multi-Attribute-Util­
ity-Scale (MAU) measurement instrument [18] that 
measures quality of life in 15 dimensions: moving, vision, 
hearing, breathing, sleeping, eating, speech, eliminating, 
vitality, mental functions, discomfort and symptoms, 
depression, distress, energy and sexual activity. Each 
dimension has a single question with 5 possible answer 
options. The 15D can be used as a profile measure or to 
give a single index score by means of population-based 
preference weights. The index score is between 0 (being 
dead) and 1 (being totally healthy). Completing the 15D 
questionnaire takes 5–10 minutes and it describes the 
respondents HRQoL at that point in time. The minimum 
clinically important difference (MCID) in the 15D single 
index score is interpreted as a difference of ± 0.03 or more, 
which corresponds to the minimum difference that peo­
ple can generally distinguish [19]. The 15D favourably 
compares with other quality of life instruments–such as 
EuroQol (EQ-5D), Health Utility Index (HUI 1–3), Short 
Form- 36 (SF-36), and the Nottingham Health Profile 
(NHP)–in most of the important properties (e.g. respon­
siveness, reliability and validity) [20-22]. 
To evaluate the patients' sense of well-being, we used VAS, 
which is a health-state rating scale. The measurement con­
sists of a line on a page with clearly defined endpoints. 
The most preferred health state is placed at one end of the 
line and the least preferred at the other end [23,24]. In this 
study, VAS was a horizontal 100 mm long line (100 mm= 
100%) illustrating the patients' health state deficiency at 
that moment. It was used to evaluate the effect of arthritis 
on health. Patients were asked to mark on the line which 
part of the deficiency of health is due to arthritis. The 
higher the number was–on scale from 0 to 100–the more 
powerful was the effect of arthritis. In addition, the 
patients' self-reported state of health was described with a 
http://www.hqlo.com/content/5/1/16 
five-point scale, representing health states from excellent 
to worst. 
Statistical analysis 
At the baseline (when placed on the waiting list) descrip­
tive statistics were used to describe the socio-demographic 
and clinical characteristics of the patients. Comparative 
variance analyses of socio-demographic and clinical char­
acteristics were described by using either an independent 
samples t-test or the Chi-square test depending on 
whether it was a continuous or nominal scale. The differ­
ences in each of the 15D dimensions and the overall 15D 
single index score for patients were calculated. Two-sided 
p-values were calculated with the Levene Test for Equality 
of Variances, with the minimum significance level set at 
5% (P-value < 0.05). The mean differences between each 
of the dimensions were also calculated. Missing values for 
the 15D were predicted by means of a regression model 
with the patient's responses for other dimensions, and 
also with data from the patients, with age and gender as 
explanatory variables [22]. The missing values were esti­
mated if a minimum of 80% of dimensions had been 
completed. Furthermore, the incidences of co-morbid 
diagnoses and also the mean 15D score were calculated 
for each diagnosis group in the model. Data analyses were 
performed using SPSS version 12.0.1 for Windows. 
Results 
Of the 914 eligible patients recruited into this study, 
twenty one were excluded because they didn't return the 
questionnaire, leaving 893 patients in the study group. 
The mean age of patients waiting for TJR was 66 years 
(range 24–88) and 63% of the participants were female. 
Patients with co-morbidity totaled 649, while patients 
without co-morbidity totaled 244. The mean age in the 
patients with co-morbidity was 67 years (range 25–87), 
versus 64 years (range 24–88) without co-morbidity (P < 
0.001). Patient's demographics are reported in Table 1. 
The incidence of co-morbidity as a secondary or tertiary 
illness was 73%. The mean number of co-morbidities 
among the patients was two, and 363 (56% of co-morbid 
patients) had three or more diagnosis. The BMI was high 
in both groups (>25 which is the limit of overweight and 
>30 is a limit of obese) but in the co-morbid group, the 
BMI was higher than in the patients without co-morbidity 
(P < 0.001). The patients' health state based on the five­
point scale was worse in the co-morbidity group. However 
in the patients with co-morbidity, the effect of the OA in 
the health-state deficiency as measured by VAS was 62% 
versus 76% (P < 0.001) in the patients without co-mor­
bidity (Table 1). 
The most common secondary diagnosis was cardiovascu­
lar disease (n = 419, 63%), followed by high cholesterol 
(n = 225, 33%), diabetes mellitus (n = 225, 33%) and 
Page 3 of 6 
(page number not for citation purposes) 
  
  
 
 
  
  
 
 
 
 
 
 
  
 
  
 
 
 
 
 
   
Health and Quality of Life Outcomes 2007, 5:16 http://www.hqlo.com/content/5/1/16 
Table 1: Demographic and clinical characteristics of TJR patients with and without co-morbidity when placed on the waiting list. 
Independent Sample T-test or Chi-square test 
Characteristics Patients with co-morbidity Patients without co-morbidity P-value 
(n = 649–6621) (n = 242–2441) 
Age, years (mean ± SD) 67 ± 10 64 ± 11 0.000*** 
Females [n, (%)] 422(63) 132 (54) 0.008** 
Marital status [n, (%)] 
Married 411 (62) 160 (65) 0.155 
Housing [n,%] 
Living alone 227 (34) 62 (25) 0.008** 
Basic education [n,%] 
Low level 544 (82) 190(78) 0.130 
Professional examination [n,%] 
Low level 486 (75) 175 (73) 0.279 
Employment status {n, (%)] 
Retired 546 (82) 172(71) 0.000*** 
Health status [n, (%)] 
Fair or poor 497 (75) 133 (55) 0.000*** 
VAS2 (mean ± SD) 62 ± 26 76 ± 24 0.000*** 
BMI3 (mean ± SD) 28.8 ± 4 27.2 ± 4 0.000*** 
1Number of observation varies due to missing values; 2VAS, visual analog scale (100 the worst, 0 the best value); 3BMI, body mass index (wt/ht2); ** 
P < 0.01, ***P < 0.001 
endocrinological problems (n = 225, 33%). The worst 
15D score of 0.637 was for a patient with mental prob­
lems (Table 2). 
At baseline the 15D score in patients with and without co­
morbidity was 0.778 vs 0.816, respectively. The difference 
of the score (0.038) was clinically and statistically signifi­
cant (P < 0.001). The patients' scores with and without co­
morbidity on the different 15D dimensions related to 
OA–moving, sleeping, usual activities, discomfort and 
symptoms, vitality and sexual activity–were low in both 
groups. Patients with co-morbidity scored lower on the 
dimensions of moving, vitality and sexual activity com­
pared to the patients without co-morbidity, while patients 
without co-morbidity scored lower in the dimensions of 
seeing, hearing, breathing and elimination. The deteriora­
tion of HRQoL was significantly associated with co-mor­
bidity (Table 3). 
Discussion 
The aim of this study was to assess the effect of co-morbid­
ities on HRQoL at baseline in patients awaiting major 
joint replacement in four Finnish hospitals. The main 
finding of this study was that the HRQoL of all TJR 
patients was poor but significantly worse in the patients 
with co-morbidity. A secondary finding was that the VAS 
health-rating instrument appears more appropriate as a 
disease-specific instrument, as in this study, patients did 
not necessarily assign the primary disease (arthritis in 
most cases) as being the most prominent in affecting their 
well-being. Furthermore, the five-point self-rated health 
scale showed that the health state of patients with co-mor­
bidity was worse than the patients without co-morbidity, 
Table 2: The co-morbidities among osteoarthritis patients and the mean 15D score in each diagnose groups, when placed on the 
waiting list for TJR 
Co-morbidity Patients, n (%) 15D (± SD) 
Cardiovascular disease 419 (63%) 0.775 (± 0.09) 
High cholesterol 225 (34%) 0.769 (± 0.09) 
Diabetes mellitus 225 (34%) 0.769 (± 0.09) 
Endocrinological problems 225 (34%) 0.769 (± 0.09) 
Other muskuloskeletal diseases 117 (18%) 0.758 (± 0.09) 
Respiratory diseases 91 (14%) 0.758 (± 0.09) 
Visual or hearing problems 54 (8%) 0.780 (± 0.07) 
Tumors 25 (4%) 0.735 (± 0.08) 
Mental problems 14 (2%) 0,637 (± 0.09) 
Page 4 of 6 
(page number not for citation purposes) 
  
  
 
 
  
 
 
 
 
 
 
 
 
 
 
Health and Quality of Life Outcomes 2007, 5:16 http://www.hqlo.com/content/5/1/16 
Table 3: 15D dimensions and score at baseline in total joint replacement patients withand without co-morbidity. Levene's Test for 
Equality of Variances 
Dimensions Patients co-morbidity (n = 662) Patients no co-morbidity (n = 242) 
Mean SE Mean SE Mean difference P-value 
Moving 0.590 0.137 0.626 0.137 0.036 0.000*** 
Seeing 0.905 0.181 0.934 0.152 0.030 0.015* 
Hearing 0.915 0.154 0.945 0.129 0.031 0.003** 
Breathing 0.812 0.235 0.937 0.138 0.125 0.000*** 
Sleeping 0.723 0.217 0.738 0.210 0.014 0.375 
Eating 0.991 0.057 0.997 0.032 0.006 0.051 
Communication 0.986 0.070 0.993 0.046 0.007 0.102 
Elimination 0.827 0.216 0.910 0.162 0.083 0.000*** 
Usual activities 0.643 0.222 0.679 0.239 0.036 0.045* 
Mental 0.889 0.176 0.906 0.162 0.017 0.180 
Discomfort and 0.506 0.236 0.540 0.240 0.033 0.065 
symptoms 
Depression 0.837 0.171 0.854 0.167 0.016 0.196 
Distres 0.848 0.177 0.865 0.162 0.017 0.168 
Vitality 0.737 0.179 0.789 0.153 0.052 0.000*** 
Sexual activity 0.732 0.281 0.783 0.243 0.051 0.008** 
15D-index 0.778 0.092 0.816 0.281 0.038 0.000*** 
*P < 0.05; **P < 0.01;***P < 0.001 
which is in line with our results of a decline from the base­
line of HRQoL as measured by 15D. 
Few studies have assessed the effect of co-morbidities on 
the quality of life (QoL) by either a generic or a disease­
specific instrument. In 1999 Xuan et al. [2] reported how 
different measuring methods differ when evaluating the 
different effects of co-morbidities related to QoL. They 
found that co-morbidity extensively affects generic QoL, 
whereas the effect is considerably smaller for disease-spe­
cific measures. Salaffi et al. [17] studied the relationship 
between OA, co-morbidity and HRQoL in older adults 
compared with matched healthy controls. They found 
that 55% of patients reporting at least one chronic coexist­
ing disease and OA of the lower extremities suffer a signif­
icant impact on multiple dimensions of HRQoL 
compared with healthy controls. The most significant 
impacts were seen in physical functions, physical roles, 
and pain. Both of these findings are in line with our 
results. 
Cardiovascular disease is the most common disease in 
Finland [1] and in our study, it was also the most com­
mon coexisting disease. According to Shan et al. [14] if OA 
is related in some way to a co-morbidity i.e. cardiovascu­
lar disease, it might negatively affect the outcomes of the 
joint replacement. Furthermore, several studies have testi­
fied that arthritis is considered to be a risk factor for other 
co-morbidity conditions such as hypertension, heart dis­
ease, diabetes and chronic lung disease [17,25]. 
Limitations of this study include the severity of the co­
morbidity not being known, and the fact that arthritis was 
necessarily classified as the primary disease. However, we 
can assume that the patients' coexisting diseases were not 
life threatening, because the severity of the co-morbidity 
in the patients is usually an exclusion criterion for the sur­
gical operation. The other limitation related to co-mor­
bidity data was that the data was collected from the 
patients, not from the patient's medical records. However 
the patients were asked to name only those co-morbidities 
diagnosed by a medical doctor. 
Co-morbidity has been commonly measured as an index 
in studies where medical records have been used to inves­
tigate mortality, complications or the costs of the medical 
care. A significantly strong association between co-mor­
bidity and mortality, complications and increasing in hos­
pital costs [2,12,14,25-28] has been shown, but to our 
knowledge there are no previous studies on the effect of 
co-morbidity on the HRQoL in the patients waiting for 
TJR. 
Our findings show statistically significant differences in 
the 15D-index between the groups with and without co­
morbidity. This suggests that a generic measurement 
instrument is sensitive enough to identify the effects of co­
morbidities. This study provides evidence of co-morbidity 
being a factor that significantly affects HRQoL, and which 
can be assessed when the patients are placed on the wait­
ing list. Moreover, some studies have suggested that the 
use of a generic HRQoL measurement in the studies of OA 
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where co-morbidity is common would be useful in char­
acterizing the global burden of this disease [16,17]. 
Conclusion 
Severity of OA was the only inclusion criteria of patients 
when placed on the waiting list, and the surgery was per­
formed according to the hospital's routine procedure, this 
study had no effect to this. In these analyses, we found 
that the HRQoL of all TJR patients was poor but signifi­
cantly worse in the patients with co-morbidity. Further, 
VAS health-rating instrument appears more appropriate 
as a disease-specific instrument, as being the most promi­
nent in affecting patients' well-being, and also the five­
point self-rated health scale showed that the health state 
of patients with co-morbidity was worse than the patients 
without co-morbidity. Assessing the co-morbidity condi­
tion at baseline might operate as an instrument to help in 
prioritization in medical decision-making for healthcare 
delivery. The assessment of co-morbidities during waiting 
time is important as well as evaluating how the co-mor­
bidity may affect the final outcomes of the whole proce­
dure. 
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Summary 
Objective: To evaluate the effect of waiting time on health and quality of life outcomes and costs of medication in total hip replacement (THR)
 
patients in a randomized clinical trial.
 
Methods: 395 THR patients were recruited into the study. When placed on the waiting list, patients were randomized into a short (�3 months)
 
or a non-ﬁxed waiting time (NFWT) (>3 months) group. In the ﬁnal analyses 309 patients (179 women) with a mean age of 65 years were
 
included. Health-related quality of life (HRQoL) (generic 15D), and pain and function (modiﬁed Harris Hip Score (HHS)) were calculated
 
when placed on the waiting list, at hospital admission, and at 3 and 12 months postoperatively. The costs of disease-speciﬁc medication
 
were calculated at the same measurement points. All analyses were performed using the intention-to-treat (ITT) principal.
 
Results: Of the recruited patients, 309 (78%) completed the follow-up (short group 140 and non-ﬁxed group 169 patients). The mean waiting
 
time was 74 days in the short and 194 days in the NFWT groups. In the ITT analyses there were no statistically signiﬁcant differences between
 
the groups in the weekly use and costs of medication, HRQoL or HHS at baseline, at admission, or 3 or 12 months after surgery. The only
 
difference was in total medication costs during the waiting time period, at EUR 83 and 171, respectively.
 
Conclusions: The length of the waiting time did not generate different effects on the studied health and quality of life outcomes of the randomized
 
groups. However, those in short waiting time group reached earlier better HRQoL.
 
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
 
Key words: Waiting time, Randomization, HRQoL, 15D, Harris Hip Score, Medication.
 
Introduction 
According to the Health 2000 Health Examination Survey in 
Finland, 12% of the population aged over 65 had hip arthri­
tis1, while 8460 total hip replacements (THRs) were per­
formed in 2004 with the median waiting time to surgery 
being 153 days. Between 1987 and 2004, the THR rate 
rose on average 5% annually2. In 2005, the Finnish Social 
Insurance Institution paid EUR 85 million in drug reimburse­
ments to 990,637 patients with musculoskeletal diseases, 
with the mean cost per patient being euro (EUR) 86 per 
year . 
*Address correspondence and reprint requests to: Ulla 
Tuominen, National Research and Development Centre for 
Welfare and Health, Lintulahdenkuja 4, FI-00531 Helsinki, 
Finland. Tel: 358-503399646; Fax: 358-939672485; E-mail: ulla. 
tuominen@thl.ﬁ, harri.sintonen@helsinki.ﬁ, johanna.hirvonen@ 
thl.ﬁ, seppo.seitsalo@invalidisaatio.ﬁ, pekka.paavolainen@invalidi­
saatio.ﬁ, matti.lehto@pshp.ﬁ, kalevi.hietaniemi@hus.ﬁ, marja.blom 
@helsinki.ﬁ 
Earlier studies have established that arthritis causes pain, 
reduces the range of motion, and creates difﬁculties in partici­
pating in daily activities, which in turn affect quality of life. Be­
cause the waiting times for surgery are long, the disease 
becomes an increasingly chronic burden to patients4e7. More­
over, the duration of conservative treatment and the use of 
medication (analgesics and anti-inﬂammatory drugs) increase 
with longer waiting time. Prior studies have demonstrated that 
poorer health status preoperatively is predictive of higher out­
of-pocket costs for patients during the ﬁrst year postopera­
tively8, and waiting more than 6 months is associated with 
higher mean total costs while longer waiting times results in de­
terioration in physical function while waiting7 . 
The aim of this prospective randomized controlled trial was 
to identify the effects of waiting time on health and health-re­
lated quality of life (HRQoL) outcomes and the use and costs 
of disease-speciﬁc medication (DSM) among two patients 
group; a short waiting time group (SWT) (�3 months) and 
a non-ﬁxed waiting time (NFWT) group (>3 months). Mea­
surements took place when ﬁrst placed on the waiting list, 
Received 19 August 2008; revision accepted 18 March 2009. at admission, and 3 and 12 months after the THR. 
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To our knowledge no prior studies have looked at the ef­
fect of waiting time on HRQoL and the use and costs of 
DSM among hip replacement patients in a randomized 
study design. The question of whether the length of waiting 
time for THR affects the use and costs of medication and 
health and quality of life outcomes is a contested issue. 
Methods 
DATA COLLECT ION 
Between August 2002 and November 2003, 513 THR patients in three 
Finnish hospitals were invited to participate in the study: two of the hospitals 
(the Surgical Hospital and Jorvi Hospital) are part of the Helsinki University 
Central Hospital, while the third is the Coxa Hospital for Joint Replacement . 
Patients were recruit ed into the study through contact with orthopedic and 
practice staff. 
The key inclusion criteri a were the need for a primary THR due to osteo­
arthritis of the hip joint as evaluated by the hospital surgeon, the patient was 
aged 16 or older and placed on the waiting list in a resea rch hospital, and the 
patient was willing and mentally able to participate in the study. The key ex­
clusion criteria were patients with rheumatoid arthrit is, fractures, and congen­
ital haemophilia or congenital deformities. 
RANDOMI ZATION 
When placed on the hospital waiting list, patients were randomly as­
signed to one of two groups: (1) a SWT with a maximum wait of 3 
months, or (2) a NFWT with surgery perf ormed according to the hosp ital’s 
routi ne procedure, wit h the waiting period measured from the date the pa­
tient was added to the waiting list to the date of admission for surge ry. 
The number of patients placed on the waiting list varied from 1 month 
to another, being speciﬁc to each hospital. Therefore, no advance esti­
mat e could be made of the number of patients to be placed on the list. 
The patient s randomized int o the SWT group could only be operated 
on in one of four operating periods during the year, and only hal f of the 
hospital’s 1-mont h surgical capacit y could be allocate d to the SWT group, 
so the number of SWTs was rest ricted and determined speciﬁcally for 
each hospital. 
Patients were recruited into the study in over three (for one of the hospi­
tals) or four recruitment periods (for the other two hospitals), each period last­
ing 3 months in order to avoid the waiting time for the SWT group exceeding 
3 months. Patients in the SWT group were operated within 2 weeks following 
the end of each recruitment period. The size of the NFWT group was not re­
stricted so as to ensure that all eligible patients placed on the waiting list had 
an opportunity to be recruited to the study. Randomization took place during 
the whole recruitment period (3 months), allowing everyone the possibility of 
a SWT. The two patient groups therefore differe d in size. 
Computer-g enerated randomization sequences were produced by the 
National Research and Development Centre for Welfare and Health and sup­
plied to the hospitals using consecutively numbered and sealed opaque en­
velopes. The patient’s named nurse assigned participants to their groups 
after the decision for surgery had been made. The randomiza tion envelops 
contained informa tion on whether the patient belonged to the SWT or 
NFWT group. Surgeons were blind to patient allocation. For ethical reasons 
double-bli nding was not possible. 
Patients completed a self-adminis tered questionnaire when placed on the 
waiting list, at admission, and at 3 and 12 months postoperatively. The 
Invited to participate (n=513) 
Excluded (n=118) 
Refused (n=103) 
Did not understand 
Finnish or Swedish (n=2) 
Other reasons (n=13) 
Randomized (n=395) 
Allocated to Short WT group 
(n=174) 
Completed baseline measurement 
(n= 168) 
Allocated to Non-fixed WT group 
(n= 221) 
Completed baseline measurement 
(n= 216) 
Lost to follow-up (n=47) 
Surgery was cancelled (n=8) 
Exited the queue (n=3) 
Died (n=5) 
Operated elsewhere (n=6) 
Did not return the form (n=25) 
Lost to follow-up (n=28) 
Surgery was cancelled (n=4) 
Exited the queue (n=1) 
Died (n= 2) 
Operated elsewhere (n=1) 
Did not return the form (n=20) 
Analysed (n= 140) Analysed (n=169) 
Fig. 1. Flow of patients through the trial. 
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Table I 
Baseline characteristics of randomized groups and those lost to follow-up 
Characteristics at baseline SWT (n ¼ 145) NFWT (n ¼ 175) Lost to follow-up P-value* 
(n ¼ 64) 
Age, years (mean � SD) 66 � 9.8 64 � 10.1 68 � 10.1 0.053 
Females [n, (%)] 88 (49.2) 91 (52.3) 38 (62.3) 0.539 
Housing [n, (%)] 
Living alone 50 (33.6) 45 (26.5) 20 (33.9) 0.313 
Basic education [n, (%)] 
Lower level 118 (79.2) 133 (78.7) 46 (78.0) 0.494 
Comorbidity, yes [ n, (%)] 103 (69.1) 116 (68.2) 40 (67.8) 0.504 
Medication to arthritis, yes [n, (%)] 136 (91.3) 149 (87.6) 56 (94.9) 0.136 
Medication costs V/week � SD 5.4 � 5.8 6.3 � 7.0 5.5 � 7.2 0.997 
BMIy � SD 27.9 � 3.9 27.7 � 3.8 27.7 � 4.6 0.865 
HHSz � SD 43.9 � 13.5 44.09 � 14.4 44.3 � 12.9 0.853 
Pain score � SD 16.8 � 7.6 17.4 � 6.8 16.2 � 7.0 0.388 
Function score � SD 27.1 � 8.6 27.2 � 9.0 27.7 � 8.1 0.612 
15D score** (mean � SD) 0.767 � 0.09 0.764 � 0.12 0.753 � 0.01 0.295 
*Between patients who completed all questionnaires and those lost to follow-up. 
yBody mass index (kg/m2).
 
zThe scale 0e91, worst to best.
 
**The scale 0e1, worst to best.
 
questionnair es were either distributed to the patients at the hospital or in 
some cases mailed to patients, as happened with one hospital for the third 
and fourth questionnaires. All questionnaires were returned by post. Com­
mon guidelines for administering the questionnair es were provided in each 
hospital. The patients completed a sociodemographic form, reported their 
medication and comorbidities as diagnosed by a medical doctor, and com­
pleted the disease-speciﬁc modiﬁed Harris Hip Score (HHS) and a separate 
questionnair e for HRQoL. Each patient provided informed consent. The 
study was approved by the Helsinki Univers ity Central Hospital Surgery 
Ethics Committee. 
MEASUREM ENT INSTRUMENT S 
HRQoL was measured by the generic 15D instrument. The 15D is com­
posed of 15 dimensions: moving, vision, hearing, breathing, sleeping, eating, 
speech, eliminating, vitality, usual activities, mental function, discomfort and 
symptoms, depression, distress, and sexual activity. Each dimension has 
ﬁve ordinal levels to choose from. The 15D can be used as a proﬁle measure 
or to give a single index score by means of population-based preference 
weights. The index score (15D score) ranges from 0 (dead) to 1 (completely 
Fig. 2. The distribution of patients by waiting time in the randomized 
groups. 
healthy)9 . Completing the 15D questionnaire takes 5e10 min and it de­
scribes the HRQoL of the respondent at present. A difference of >j0.03j in 
the 15D score is clinically important in the sense that on average people 
can feel the difference10. In most of the important properties (reliability, con­
tent validity, sensitivity in terms of discriminatory power and responsiveness 
to change) the 15D compares at least equally with other similar instruments 
that produce a valuation-based single index number10e14 . 
By using the mean 15D scores from each measuremen t point and assum­
ing a linear change in the scores between the measurement points we also 
estimated the possible gain in quality-adjusted life years (QALY gain) for 
both groups within the observation period. 
The disease-speciﬁ c modiﬁed HHS was used to measure hip pain and 
function. The self-re port HHS consists of two sections: pain (0e44 points) 
and functional activities of daily living and gait (0e47). The total score ranges 
from 0 to 91, with higher scores represent ing better health states15. A further 
9 points of the total HHS would normally be assigned to describing deformity 
and range of motion, but were excluded because these items could not be 
measured in a patient self-re port questionnaire. The performance of self-re­
ported HHS is comparable to that of surgeon-assessed HHS and has shown 
to be less burdensome to patients than physician-administer ed HHS16. The 
HHS and 15D score serve as measures of disease severity at baselin e 
(preoperatively). 
The use of DSM (analgesics and anti-inﬂammat ory drugs) during the 
week preceding every measurement point was measured based on self-re­
port. The unit costs of medication per tablet were obtained from CD-Phar­
17macy . The costs of medication during the waiting period were calculated 
as a product of the weeks spent on the waiting list and the medication costs 
per week. The calculat ions for medication costs were made at each of the 
four measurement points. 
STATISTICAL ANALYSI S 
The sample size estimate was based on the primary outcome variable 
15D. A subgroup of 177 patients would provide the 80% power (two-tailed 
a error 5%) to detect clinically important differe nces (D0.03) in the 15D score 
between the randomized groups. 
Primary analyses were conducted with an intention-to-treat (ITT) 
principle18, so that patients were followed in the groups to which they 
were randomly allocated. Also a supplementary per-pro tocol analysis 
was carried out at admission by excluding the patients from SWT group 
who were admitted beyond the short waiting time (waiting time > 3 
months). When comparing the mean scores of 15D, total HHS, pain, func­
tion and costs of DSM at the various points of follow-up between SWT and 
NFWT, general linear model for repeated measures was used. Univariat e 
(tests of within-subject effects) P-values were calculated, while a P-value 
<0.05 was considered statistically signiﬁcant. Also the mean differences, 
standard deviations and conﬁdence intervals (CIs) of 95% of the variables 
15D, total HHS, pain, function and costs of DMS were presented for the 
estimated effect. 
Descriptive characteris tics at baselin e in the randomized groups and the 
patients who were lost to follow-up were compared using either the F-test or 
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Table II 
Outcomes at admission, ITT-analysis 
Outcome measure SWT mean (�SD) NFWT mean (�SD) Mean difference 95% CI P-value 
(n ¼ 139e140) (n ¼ 167e169) 
15D score* 0.768 (0.107) 0.769 (0.107) 0.001 �0.022 to 0.024 0.931 
Self-report HHSy
HHS pain score 
42.99 (15.32) 
17.63 (7.64) 
41.73 (14.08) 
17.14 (8.55) 
�1.262 
�0.493 
�5.233 to 1.816 
�2.332 to 1.346 
0.456 
0.602 
HHS function score 25.86 (9.08) 24.79 (8.42) �1.067 �3.051 to 0.915 0.29 
Costs of medicationz 5.56 (6.80) 5.63 (6.22) 0.793 �1.399 to 1.557 0.916 
Costs of medication** 81.3 (129.54) 171.3 (264.36) 88.49 42.49 to 134.90 0.000*** 
Waiting time, days 74 (145) 194 (175) 117.80 93.03 to 142.57 0.000*** 
***P < 0.001. 
*The scale 0e1, worst to best. 
yThe scale 0e91, worst to best. 
zWeekly costs of medication in EUR (EUR is 1.6 US$). 
**Medication costs during the waiting time. 
the chi-squared test, depending on whether the variable was on a continuous 
or nominal scale. 
Missing values on the 15D were replaced if a minimum of 80% of dimen­
sions had been completed, using a regression model with the patient’s re­
sponses for other dimensions, age and gender as explanatory variables11 . 
Data analyses were performed using SPSS versions 14 and 16 for Windows. 
Results 
Of the 513 eligible patients invited to participate in the 
study, 118 refused to participate and were excluded. Their 
mean age was 70 years (SD � 11) and 64% were women. 
The most frequently quoted reasons for refusal were being 
too tired or unwillingness to complete questionnaires. Thus, 
395 patients after providing a signed informed consent were 
randomly allocated to either the SWT (n ¼ 174) or NFWT 
(n ¼ 221) group. Of these patients, 86 were lost to follow­
up during the waiting time and were not included in the ﬁnal 
analyses. Of these patients 11 did not return the question­
naire at baseline, although they had signed informed con­
sent and were randomized, seven were operated on 
elsewhere, operations for 12 patients were canceled, and 
seven died while waiting and 45 did not return the question­
naire at admission. All analyses are based on 309 (78%) 
patients (179 women) with a mean (SD) age of 65 (�9.9; 
range; from 33 to 87) years, of which 140 were in the 
SWT and 169 in the NFWT group (Fig. 1). 
BASELINE CHARACTERISTICS 
The baseline characteristics of the groups were similar 
and are reported in Table I. The mean (�SD) 15D score 
in the SWT group was 0.767 (�0.09) and 0.764 (�0.12) 
in the NFWT group; the difference was not statistically sig­
niﬁcant or clinically important (P ¼ 0.295). The mean (�SD) 
total HHS was 43.9 (�13.6) and 44.1 (�14.1) in the SWT 
and NFWT group, respectively (P ¼ 0.853). The percentage 
of patients receiving DSM was 91% (n ¼ 136) in the SWT 
and 89% (n ¼ 149) in the NFWT group. The mean weekly 
medication costs were EUR 5.4 and EUR 6.3 in the SWT 
and NFWT groups, respectively. The difference was not 
statistically signiﬁcant (Table I). 
A comparison between patients who completed the 
questionnaire and those who were lost to follow-up showed 
no statistically signiﬁcant differences between the groups 
(Table I). 
OUTCOMES AND WAITING TIME 
At admission there was a statistically signiﬁcant differ­
ence in mean waiting time between the groups: 74 (�145) 
days in the SWT and 194 (�175) days in the NFWT group 
(95% CI: 93.03e142.57, P < 0.001) (Fig. 2). There were no 
statistically signiﬁcant differences between the groups in the 
mean 15D score, total HHS, pain and function or in the 
weekly cost of medication. However, due to a shorter wait­
ing time the total cost of DSM during the waiting period was 
lower in the SWT group (EUR 81.3) than in the NFWT group 
(EUR 171.3) (95% CI: 42.49e134.90, P < 0.001) (Table II). 
A per-protocol analysis was performed as a supplemen­
tary analysis. In the SWT group (n ¼ 92), those compliant 
with allocated waiting time 59 (�21) days and all patients 
(n ¼ 170) in the NFWT group were included in the analysis. 
Similar results were obtained in a per-protocol analysis as in 
ITT analysis (Table III). 
Table III 
Outcomes at admission, per-protocol analysis 
Outcome measure SWT mean NFWT mean Mean difference 95% CI P-value 
(�SD) (n ¼ 92)* (�SD) (n ¼ 170) 
15D-score 0.764 (0.11) 0.770 (0.11) 0.004 �0.023 to 0.032 0.733 
Self-report HHS 42.95 (16.27) 41.73 (14.0) �1.251 �5.198 to 2.766 0.548 
HHS pain score 17.42 (8.18) 17.14 (8.56) �0.283 �2.432 to 1.866 0.795 
HHS function score 25.90 (9.47) 24.80 (8.42) �1.106 �3.442 to 1.230 0.351 
Costs of medicationy 5.22 (6.74) 5.63 (6.22) 
Waiting time days 59.28 (21.40) 218.50 (140.35) 
0.41 
159.211 
�1.277 to 2.098 
137.79 to 180.635 
0.632 
0.000*** 
***P < 0.001. 
*49 SWT patients admitted beyond SWT were excluded. 
yWeekly costs of medication in EUR (EUR is 1.6 US$). 
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Table IV 
Descriptive statistics of the outcomes in SWT and NFWT groups; mean and standard deviation 
Outcome At baseline At admission 3 months postoperatively 1-year postoperatively 
SWT NFWT SWT NFWT SWT NFWT SWT NFWT 
15D 
Mean 0.770 0.779 0.772 0.775 0.852 0.859 0.857 0.873 
�SD	 0.090 0.100 0.090 0.090 0.090 0.100 0.110 0.110 
Total HHS 
Mean 43.75 43.05 43.55 41.82 67.02 67.12 72.18 74.57 
�SD 13.78 14.58 15.27 14.48 16.54 17.15 16.91 16.9 
Function score 
Mean 26.68 26.19 26.11 24.93 34.93 35.05 39.05 39.24 
�SD	 8.73 8.95 8.97 8.56 8.41 9.04 7.67 8.5 
Pain score 
Mean 16.82 17.43 17.63 17.13 32.4 32.75 33.57 35.1 
�SD	 7.6 6.8 7.6 8.55 10 9.5 9.78 10.06 
Costs of medication (V)
 
Mean 5.06 6.41 5.31 5.57 1.59 1.96 0.8 0.98
 
�SD	 5.78 7.23 6.73 6.4 4.12 4.47 2.45 2.71 
OUTCOMES AFTER THR 
The use and costs of medication had decreased in both 
groups at 3 months and 1 year after the THR: 43% 
(n ¼ 55) in the SWT and 48% (n ¼ 71) in the NFWT group 
reported using medication for arthritis. In the SWT group 
the weekly costs at 3 months were EUR 1.58 and in the 
NFWT group EUR 1.96 and after 1 year EUR 0.80 and 
EUR 0.98, respectively. The differences were statistically 
signiﬁcant between different measurement points 
(F ¼ 63.08; P < 0.001), but not between the randomized 
groups (F ¼ 1.08; P ¼ 0.372). 
At 3 months the mean 15D score was 0.852 in the SWT 
and 0.859 in the NFWT group, and after 1 year 0.856 and 
0.873, while the mean total HHS was after 3 months 
67.02 and 67.12, respectively and after 1 year 72.18 and 
74.57, respectively. The differences between the groups 
are not statistically signiﬁcant (Table IV). There were statis­
tically signiﬁcant differences between different measure­
ment points, but not between the randomized groups 
(Table V). 
There was an improvement from 3 months to 12 months 
postoperatively in the mean 15D score and total HHS, pain 
and function and a decrease in the cost of medication in 
both groups. SWT resulted in a gain of 0.028 QALYs 
Table V 
Effect of the waiting time in the randomized groups. General linear 
model, repeated measures analysis, tests of within-subjects effect 
Measurement Source F P-value 
instrument 
15D	 Time 207.324 0.000* 
Time � randomized group 0.694 0.531y 
HHS	 Time 470.763 0.000* 
Time � randomized group 1.429 0.239y 
Function score	 Time 308.701 0.000* 
Time � randomized group 0.703 0.511y 
Costs of Time 86.104 0.000* 
medication Time � randomized group 1.04 0.365y 
*Time effect e differences between the four measurement 
points. 
yGroup effect e differences between randomized groups. 
(area between the curves in Fig. 3) during the observation 
period. 
Conclusions 
Scientiﬁc evidence on the relationship between waiting 
time and THR outcomes is inconsistent and the absence 
of randomized trials has prevented an assessment of 
whether longer waiting is somehow related to health and 
quality of life outcomes. To our knowledge, the present 
study is the ﬁrst to assess the use and costs of DSM in 
THR patients randomly allocated to short and NFWT 
groups. The study also analyzed whether the length of the 
waiting time was related to HRQoL, hip pain and function 
as measured by the 15D and HHS, respectively. 
The main ﬁnding was that the time spent on the waiting 
list was not related to the weekly use and costs of DSM, 
with no differences found between the randomized groups. 
The weekly costs were almost identical in both groups at 
each of the four measurement points. In an earlier study 
among these patients it was found that they used very little 
health and social services during the waiting time and only 
a minority of patients received visits to their home from 
nurse, chiropodist or physician with no statistically 
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Fig. 3. The QALY gain (area between the curves) due to short 
waiting time during the observation period. 
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signiﬁcant difference between the randomized groups 19 . 
Similarly, the mean HRQoL scores and pain and function 
scores were almost identical in both groups at each of 
the four measurement points, and reached their highest 
values 12 months postoperatively. However, the SWT re­
sulted in a small QALY gain of 0.028, and reached better 
quality of life 3 months earlier than those in the NFWT 
group. 
In this study, patients’ HRQoL at baseline was deterio­
rated and they had pain and difﬁculties in functioning and 
daily activities. However, the length of waiting time alone 
did not affect HRQoL or pain and function scores, which 
is in line with the ﬁndings of some earlier studies4,5,7,20,21 . 
However THR has been found to be effective12,13,22,23 , 
with this study also showing signiﬁcant improvement in 
HRQoL and in pain and function 3 and 12 months postop­
eratively in both randomized groups. 
To our knowledge no studies have so far been published 
on the effect of waiting time on the use and costs of DSM. 
Fielden et al.6 estimated the costs and outcomes of the 
waiting time for THR in a prospective study. They found 
that waiting more than 6 months was associated with higher 
total costs and deterioration in physical function while wait­
ing. These cost results are not comparable to ours, as they 
estimated all costs during the waiting period6 . 
The strengths of this study were that the patients awaiting 
THR were prospectively followed from the time of being 
placed on the waiting list to admissiondwith waiting times 
recorded preciselydand for a further year of follow-up 
postoperatively, providing evidence of the effect of WT on 
pre- and postoperative health status. Further the patients 
were randomly assigned to either a SWT or NFWT group. 
The ﬁndings were based on the simultaneous use of pa­
tient-reported generic and disease-speciﬁc instruments as 
outcome measures. Also the results based on ITT and 
per-protocol analyses indicated that there were no statisti­
cal signiﬁcant differences in health outcomes between the 
randomized groups. This was further tested with repeated 
measures analyses. The within-subject test indicated that 
there was a signiﬁcant time effect, i.e., the outcomes did 
change over time, but the changes were identical, which 
is consistent with the ﬁnding that the interaction was not 
signiﬁcant. 
Some limitations pertain to this study. First, patients 
who refused to participate the study were older than 
those in the study groups. Second, medication informa­
tion was obtained only from patient self-reports, while 
there was no distinction between self-care and prescrip­
tion medication. For temporary medication we used 
mean dosages. Third, a total of 49 patients in the SWT 
group waited more than 3 months. The reasons were 
hospitals’ limited capacity to carry out THR within the 3 
months waiting time period or the patient’s unwillingness 
to have THR within 3 months. Due to these factors, the 
differences between the randomized groups may have 
been underestimated. However the primary ana lysis 
was based on the ITT principle to address the question 
of clinical effectiven ess and to avoid the bias associated 
with a non-ra ndom loss of participants. In addition the 
supplementar y per-pro tocol analysis at admission where 
the SWT patients who were admitted beyond SWT were 
excluded from the analysis e supported the main ﬁnd­
ings and did not show a statistically or clinically important 
differen ce in HRQoL between randomized groups. 
According to this study the length of the waiting time, at 
least as realized in practice in this study, did not result in 
different health outcomes in the randomized groups in three 
cross-sectional follow-up measurements from baseline to 1­
year postoperatively. The length of the waiting time re­
ﬂected in the total medication costs of the waiting period 
and in a small QALY gain in the SWT, as it reached the 
same HRQoL level as the NFWT group on average 3 
months earlier. 
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ABSTRACT  
Background: The aim of this prospective randomized study was to evalu­
ate the effect of waiting time (WT) on health-related quality of life 
(HRQoL), knee pain and physical function, and the use and costs of 
medication of patients awaiting total knee replacement. 
Methods: When placed on the waiting list, 438 patients were randomized 
into a short waiting time (SWT � 3 months) or a nonﬁxed waiting time 
(NFWT > 3 months) group. HRQoL was measured by the 15D, and pain 
and physical function by modiﬁed Knee Society Clinical Rating System at 
baseline, admission, and 3 and 12 months postoperatively. The costs of 
medication due to osteoarthritis were calculated at the same measurement 
points. All analyses were performed using the intention-to-treat 
principle. 
Results: The mean WT was 94 and 239 days in the SWT and NFWT 
groups, respectively. Apart from higher weekly cost of medication in the 
SWT group at admission and better HRQoL in the NFWT group 1 year 
postoperatively, there were no statistically signiﬁcant differences between 
the groups in other outcomes during the follow-up. 
Conclusion: Those in the SWT group had higher weekly costs of medica­
tion at admission, and reached better HRQoL 3 months earlier than those 
in the NFWT group, but the latter had better HRQoL after operation. 
Otherwise, the length of WT was not associated with different health and 
HRQoL outcomes in the groups. 
Keywords: cost, health-related quality of life, osteoarthritis, randomized 
clinical trial, waiting lists. 
Introduction 
Osteoarthritis (OA) is the most common cause of musculoskeletal 
disability and pain in the world. In Finland, 6% of men and 8% of 
women over the age of 30 years suffer from clinically diagnosed 
knee OA. The incidence of radiological and clinical knee arthritis 
increased with age both in men and women [1]. During 2004, a 
total of 5905 total knee replacements (TKRs) were performed 
with the median waiting time (WT) to surgery being 209 days. 
According to statistics, the number of TKRs increased to 9033 and 
median WT decreased to 149 in 2006 [2]. In 2005, the Finnish 
Social Insurance Institution paid EUR 85 million in drug reim­
bursements to 990,637 patients with musculoskeletal diseases, 
with the mean cost being EUR 86 per year [3]. 
Patients with OA experience increasing pain and progressive 
loss of physical function, walking, and stair climbing [4–8]. 
Earlier studies have established that arthritis causes difﬁculties in 
participating in daily activities, which in turn affect quality of life 
[9–12]. Physiotherapy and pharmacological treatment (paraceta­
mol and nonsteroidal anti-inﬂammatory drugs) are used to 
reduce the symptoms, namely joint pain, stiffness, and swelling. 
But, if OA pain is not otherwise manageable, patients’ ability to 
manage everyday tasks is essentially compromised because of 
OA, or if there is signiﬁcant restriction of motion, or a joint 
malposition, a TKR should be performed [1]. 
Address correspondence to: Ulla Tuominen, The Social Insurance Institu­
tion, Research Department, Nordenskiöldinkatu 12 Helsinki, FI-00250 
Finland. E-mail: ulla.tuominen@thl.ﬁ 
10.1111/j.1524-4733.2010.00779.x 
In many Western countries, WTs for TKR are long [13]. In 
discussion on health policy in Finland, long WTs are regarded as 
a major problem for several reasons. They are claimed to violate 
the principle of equal access to treatment, which is a key perfor­
mance indicator of health care in Finland. They are also claimed 
to result in extra suffering, extra cost to the patients and the 
society, and poorer treatment outcomes. Nevertheless, it is 
unclear to what extent these claims are true as there is little solid 
evidence to substantiate them. 
To our knowledge, no prior studies have looked at the effect 
of WT on health-related quality of life (HRQoL) and the costs of 
disease-speciﬁc medication (DSM) among knee replacement 
patients in a randomized study design. The aim of this prospec­
tive randomized study was to identify the effects of WT on health 
and quality-of-life outcomes, and the use and costs of disease­
speciﬁc medication among two different patient groups: a short 
WT group (�3 months) and a nonﬁxed WT group (>3 months). 
The question of whether the length of WT for TKR affects the 
costs of medication and health, and quality-of-life outcomes is a 
contested issue. 
Methods 
Data Collection 
Between August 2002 and November 2003, 555 TKR patients in 
three Finnish hospitals were invited to participate in the study: 
two of the hospitals (the Surgical Hospital and Jorvi Hospital) 
are part of the Helsinki University Central Hospital, while the 
third is the Coxa Hospital for Joint Replacement. Patients were 
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recruited into the study through contact with orthopedic and 
practice staff. 
The key inclusion criteria were the need for a primary TKR 
due to OA of the knee joint as evaluated by the hospital surgeon, 
the patient was adult (aged 16 or older) and placed on the 
waiting list in a research hospital, and the patient was willing and 
mentally able to participate in the study. The key exclusion 
criteria were patients with rheumatoid arthritis, fractures, and 
congenital hemophilia or congenital deformities. 
Randomization 
After being placed on the hospital waiting list, the patients were 
randomly assigned to one of two groups: 1) a short waiting time 
(hereafter SWT) with a maximum 3 months wait; or 2) a non­
ﬁxed waiting time (hereafter NFWT) with surgery performed 
according to the hospital’s routine procedure, with the waiting 
period measured from the date the patient was added to the 
waiting list to the date of admission for surgery. The number of 
patients placed on the waiting list varied from 1 month to 
another, being speciﬁc to each hospital. Therefore, no advance 
estimate could be made of the number of patients to be placed on 
the list. 
The patients were recruited into the study in three (in one 
hospital) or four recruitment periods (in two hospitals), each 
period lasting 3 months to avoid the WT for the SWT group 
exceeding 3 months. Patients randomized into the SWT group 
were operated within 2 weeks after the end of each recruitment 
period, and only half of the hospital’s 1 month surgical capacity 
could be allocated to the SWT group, so the number of SWTs 
was restricted and determined speciﬁcally for each hospital. The 
size of the NFWT group was not restricted to ensure that all 
eligible patients placed on the waiting list had an opportunity to 
be recruited into the study. The two patient groups therefore 
differed in size. 
Computer-generated randomization sequences were pro­
duced by the National Research and Development Centre for 
Welfare and Health, and supplied to the hospitals using consecu­
tively numbered and sealed opaque envelopes. The patient’s 
named nurse assigned participants to their groups after the deci­
sion for surgery had been made. The randomization envelopes 
contained information on whether the patient belonged to the 
SWT or NFWT group. Surgeons were blinded to patient alloca­
tion. For ethical reasons, double-blinding was not possible. 
The patients completed a self-administered questionnaire 
when placed on the waiting list, at admission, and at 3 and 12 
months postoperatively. The questionnaires were either distrib­
uted to the patients at the hospital or in some cases mailed to 
patients, as happened with one hospital for the third and fourth 
questionnaires. All questionnaires were returned by prepaid post. 
Common guidelines for administering the questionnaires were 
provided in each hospital. The patients completed a sociodemo­
graphic form, reported their medication and comorbidities as 
diagnosed by a medical doctor, and completed the disease­
speciﬁc modiﬁed Knee Society Clinical Rating System (KS) and a 
separate questionnaire for HRQoL. Each patient provided 
informed consent. The study was approved by the Helsinki Uni­
versity Central Hospital Surgery Ethics Committee. 
Measurement Instruments 
HRQoL was measured by the generic 15D instrument. The 15D 
is composed of 15 dimensions: moving, vision, hearing, breath­
ing, sleeping, eating, speech, eliminating, vitality, usual activities, 
mental function, discomfort and symptoms, depression, distress, 
and sexual activity. Each dimension has ﬁve ordinal levels to 
choose from. The 15D can be used as a proﬁle measure or to give 
a single index score by means of population-based preference 
weights. The index score (15D score) ranges from 0 (dead) to 1 
(completely healthy) [14]. Completing the 15D questionnaire 
takes 5 to 10 min, and it describes the HRQoL of the respondent 
at present. A difference of >|0.03| in the 15D score is clinically 
important in the sense that on average people can feel the differ­
ence [15]. The 15D was chosen for three main reasons: 1) it has 
been used successfully in earlier studies dealing with knee 
replacement and facilitates thus a comparison to the presurgery 
scores in these studies; 2) earlier research has shown that in most 
of the important properties (reliability, content validity, sensitiv­
ity in terms of discriminatory power, and responsiveness to 
change), the 15D compares at least equally with other similar 
instruments that produce a valuation-based single index number 
[16,17]; and 3) recent research has since conﬁrmed that espe­
cially in the rehabilitation of musculoskeletal disorders, the 15D 
was at least as responsive as the SF-6D, if not better. These two 
instruments were anyway the most responsive ones [18]. 
By using the mean 15D scores from each measurement point 
and assuming a linear change in the scores between the measure­
ment points, we also estimated the possible gain in quality­
adjusted life-years (QALY gain) for both groups within the 
observation period. 
The disease-speciﬁc, self-reported modiﬁed KS [19] was used 
to measure knee pain and physical function, because it has been 
found to be responsive to change [20]. Pain score (0–50 points) 
and function score (0–100 points) are presented separately; clini­
cal dimensions (range of motion, stability, ﬂexion contracture, 
extension lag, and alignment) could not be measured in a 
patient’s self-administered questionnaire, and thus the total score 
could not be derived. 
The use of DSM during the week preceding every measure­
ment point was measured based on self-report. The unit costs of 
medication per tablet were obtained from CD-Pharmacy [21]. 
The costs of medication during the waiting period were calcu­
lated as a product of the weeks spent on the waiting list and the 
medication costs per week. The calculations for medication costs 
were made at each of the four measurement points. 
Statistical Analysis 
The sample size estimate was based on the primary outcome 
variable 15D. A total subgroup of 177 patients would provide 
the 80% power (two-tailed a error 5%) to detect clinically 
important differences >|0.03| in the 15D score between the ran­
domized groups. 
Primary analyses were conducted with an intention-to-treat 
(ITT) principle [22], so that patients were followed in the 
groups to which they were randomly allocated. When compar­
ing the mean scores of 15D, knee pain, function, and costs of 
DSM at the various points of follow-up between SWT and 
NFWT, a general linear model (GLM) for repeated measures as 
tests of between-subject effects was used. P < 0.05 was consid­
ered statistically signiﬁcant. Also, the mean differences, SDs, 
and conﬁdence intervals (CIs) of 95% of the variables 15D, 
knee pain and function, WT, and costs of DSM were presented 
for the estimated effect. 
Baseline characteristics of the randomized groups and the 
patients who were lost to follow-up were compared using either 
the independent sample t test or chi-square test, depending on 
whether the variable was on a continuous or nominal scale. 
Missing values on the 15D were replaced if a minimum of 
80% of dimensions had been completed, using a regression 
model with the patient’s responses for other dimensions, age, and 
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sex as explanatory variables [14]. Data analyses were performed 
using SPSS for Windows v.14 and v.16 (Chicago, IL). 
Results 
Of the 555 eligible patients invited to participate in the study, 
117 patients (90 women) with a mean age of 71 refused to 
participate and were excluded. Thus, 438 patients after provid­
ing a signed informed consent were randomly allocated to either 
the SWT (n = 172) or NFWT (n = 266) group. Of these patients, 
13 did not return the questionnaire at baseline, although they 
had signed informed consent. During the WT, 95 patients were 
lost to follow-up, 3 exited the queue, 8 had severe comorbidities, 
Allocated to Short WT group 
(n=172) 
Completed baseline measurement
 (n=166) 
Allocated to Nonfixed WT group (n=266)
Completed baseline measurement (n=259) 
Completed admission measurement  
(n= 132) 
Lost to follow-up at (n= 34) 
Surgery was canceled (n=6) 
   Died (n=1) 
   Comorbidities (n=5) 
   Unknown reasons (n= 22) 
Completed admission measurement 
(n=198)
Lost to follow-up (n= 61) 
  Surgery was canceled (n=15) 
Exited the queue (n=3) 
 Died (n=3) 
 Comorbidities (n=3) 
 Operated in a private hospital (n=4)
 Unknown reasons (n= 33)
Randomized (n=438) 
Invited to participate (n=555)
Excluded (n=117)
Refused (n=104) 
Operated on the contralat. 
 side (n=2) 
 Did not understand Finnish
 or Swedish (n=2) 
Inmate of an institution  
 (n=1) 
Other reasons (n=8) 
Completed all four measurements
(n= 119) 
  Lost to follow-up (n=13) 
  Unknown reasons
Completed all four measurements
(n=170)
Lost to follow-up (n=28) 
Unknown reasons
In final analyses (n= 119) 
4 were operated on in a private hospital, 29 had canceled opera­
tions, 4 died while waiting, and 45 did not return the question­
naire at admission. Primary ITT analyses are based on 330 
(77%) patients (237 women) with a mean (�SD) age of 68 
(�9.9) years, of which 132 were in the SWT and 198 in the 
NFWT group, and the ﬁnal GLM repeated analyses are based on 
289 patients, who completed all four questionnaires. Of them, 
119 were in the SWT and 170 in the NFWT (Fig. 1). 
Baseline Characteristics 
The baseline characteristics of the groups were similar (Table 1). 
The mean (�SD) 15D score in the SWT group was 0.772 
In final analyses (n=170) 
Figure 1 Patients ﬂow through the trial. 
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Table 1 Characteristics at baseline in patients waiting for total knee replacement and those lost to follow-up 
SWT NFWT Lost to follow-up 
Characteristics n = 132 n = 198 n = 95 P value† P value‡ 
Age, mean � SD 67 � 9.5 68 � 8.9 69 � 9.3 0.208 0.619 
Sex (female), (n [%]) 98 (70) 139 (69) 64 (66) 0.308 0.294 
Living alone (n [%]) 50 (32) 65 (37) 33 (38) 0.180 0.900 
Professional education (n [%]) 31 (23) 38 (19) 11 (13) 0.218 0.168 
Employment status 
Retired (n [%]) 107 (81) 169 (85) 71 (83) 0.050 0.834 
Comorbidity (n [%]) 102 (77) 154 (78) 70 (81) 0.509 0.566 
Medication to arthritis (n [%]) 115 (87) 175 (88) 71 (82) 0.428 0.208 
Cost of medication €/week 5.72 � 7.2 5.91 � 6.1 4.89 � 6.2 0.803 0.456 
Body mass index (kg/m2) 29.4 � 7.0 29.4 � 4.4 28.55 � 7.1 0.121 0.43 
Pain score, mean � SD§ 19.9 � 11.8 20.92 � 12.4 19.96 � 11.0 0.355 0.030* 
Function score, mean � SD|| 48.42 � 22.1 46.95 � 23.3 52.38 � 22.6 0.567 0.171 
15D score, mean � SD¶ 0.772 � 0.108 0.779 � 0.119 0.779 � 0.11 0.539 0.835 
*P < 0.05. 
†Differences between the randomized groups. 
‡Differences between the patients who completed the questionnaire and those lost to follow-up. 
§The scale 0–50, worst to best. 
||The scale 0–100, worst to best. 
¶The scale 0–1, worst to best. 
(�0.108) and 0.779 (�0.119) in the NFWT group; the difference 
was not statistically signiﬁcant or clinically important 
(P = 0.539). The mean (�SD) pain score was 19.9 (�11.8) and 
20.9 (�12.4) in the SWT and NFWT groups, respectively 
(P = 0.355). The percentage of patients receiving DSM was 87% 
(n = 118) in the SWT and 88% (n = 181) in the NFWT group. 
The mean weekly medication costs were €5.7 and €5.9 in the 
SWT and NFWT groups, respectively. The difference was not 
statistically signiﬁcant (Table 1). 
A comparison between patients who completed the question­
naire and those who were lost to follow-up showed a statistically 
signiﬁcant difference in pain score (P = 0.030) (Table 1). 
Outcomes and WT 
At admission, there was a statistically signiﬁcant difference in 
mean WT between the groups: 95 (�81) days in the SWT and 
239 (�135) days in the NFWT group (F value 100.6; 95% CI 
116, 99–172, 22; P < 0.001). There was a statistically signiﬁcant 
difference between the groups in the weekly costs of DMS, at 
€5.33 and €3.57, respectively (F value 4.85; 95%CI 3.54–5.10; 
P = 0.029). There were no differences between the randomized 
groups in the mean 15D, pain, and function score, and in the 
costs of DSM during the WT (Table 2). 
Outcomes after TKR 
The use and costs of medication had decreased in both groups at 
3 months and 1 year after the TKR. In the SWT group, the 
weekly costs at 3 months were €3.14 and in the NFWT group 
€3.10, and after 1 year they were €1.74 and €2.96, respectively 
(Table 3). In repeated measures analyses, the differences were 
statistically signiﬁcant between measurement points (F = 13.17; 
P < 0.001), but not between the randomized groups (F = 1.17; 
P = 0.317) (Table 4). 
At 3 months, the mean 15D score was 0.813 in the SWT and 
0.837 in the NFWT group, and at 1 year they were 0.813 and 
0.852, respectively. The difference between the randomized 
groups was statistically signiﬁcant (P = 0.012) after 1 year post­
operatively. The mean pain scores were at 3 months 32.7 and 
34.1, respectively, and at 1 year they were 36.3 and 36.9, respec­
tively. The mean function scores were at 3 months 62.78 and 
63.8 in the SWT and NFWT respectively, and at 1 year 73.5 and 
74.6, respectively. The differences between the randomized 
groups were not statistically signiﬁcant (Table 3). There were 
statistically signiﬁcant differences between the measurement 
points (Table 4). 
There were improvements from admission to 12 months post­
operatively in the mean 15D score, and pain and function scores, 
and a decrease in the cost of medication in both groups. Assum­
ing that the ﬁnal mean HRQoL score in the SWT group would 
carry forward until the ﬁnal measurement point in the NFWT 
group, the latter group would gain 0.033 QALYs more than the 
SWT group during the whole observation period of almost 700 
days (the sum of two areas between the curves in Fig. 2), even if 
the SWT group would gain 0.012 QALYs more in the short run 
by reaching a better level of HRQoL earlier (the ﬁrst area 
Table 2 Outcomes at admission in total knee replacement patients, intention-to-treat analyses 
SWT NFWT 
Mean, (�SD) Mean, (� SD) 95% Conﬁdence 
Outcome (n = 133–136)* (n = 194–203)* interval for mean F value P value 
15D score 0.768 (0.15) 0.779 (0.10) -0.020 to 0.029 0.031 0.744 
Pain score 18.93 (11.8) 22.79 (12.40) -1.478 to 3.969 0.308 0.369 
Function score 48.42 (22.1) 46.95 (23.31) -6.659 to 3.493 0.737 0.540 
Cost of medication €/week 5.33 (7.55) 3.57 (5.38) 3.54 to 5.10 4.85 0.029† 
Cost of medication €/waiting time (WT) 89.19 (199.19) 120.54 (194.82) 80.75 to 131.09 1.50 0.222 
WT (days) 94.60 (81.3) 239.2 (135.1) 154.5 to 188.09 100.60 0.000‡ 
*Number of observations varies because of missing values. 
†P < 0.05, ‡P < 0.001. 
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Table 3 Outcomes after total knee replacement, intention-to-treat analyses 
Three months One year 
postoperatively postoperatively 95% Conﬁdence 95% CI 
Outcome SWT NFWT interval (CI) for mean P value SWT NFWT for mean P value 
15D score, mean 0.813 0.837 -0.002 to 0.05 0.06 0.813 0.852 0.01 to 0.07 0.012* 
�SD 0.12 0.11 0.14 0.1 
Pain score, mean 32.7 34.07 -1.55 to 4.85 0.311 36.27 36.95 -3.11 to 4.47 0.724 
�SD 13.03 13.49 13.15 12.83 
Function score, mean 62.78 63.86 -7.12 to 4.96 0.725 73.5 74.63 -4.71 to 6.98 0.703 
�SD 25.58 25.22 23.32 22.28 
Costs of medication, mean (€/week) 3.14 3.1 -1.48 to 1.20 0.838 1.74 2.96 -0.36 to 2.25 0.142 
�SD 5.88 7.29 3.96 4.07 
*P < 0.05. 
Table 4 Waiting time effect between the randomized groups 
Outcome Source F value P value 
15D Time 38.746 0.000† 
Time* 15D 1.66 0.177* 
Pain score Time 159.686 0.000† 
Time* pain score 0.645 0.563* 
Function score Time 118.47 0.000† 
Time* function score 1.102 0.346* 
Costs of medication Time 13.172 0.000† 
Time* costs of medication 1.17 0.317* 
*Difference between randomized groups. 
†Difference between the measurement points.
 
General linear model, repeated measures, test of within-subjects effect.
 
between the curves in Fig. 2), although those in the NFWT had 
better quality of life postoperatively. 
Interpretation 
Scientiﬁc evidence on the relationship between WT and TKR 
outcomes is inconsistent, while the absence of randomized trials 
has prevented an assessment of whether longer waiting is 
somehow related to health and quality-of-life outcomes. To our 
knowledge, the present study is the ﬁrst to assess the use and 
costs of DSM in TKR patients randomly allocated to SWT and 
0,9 
0,88 
0,86 
0,84 
NFWT groups. The study also analyzed whether the length of the 
WT was related to HRQoL, knee pain, and function as measured 
by the 15D and modiﬁed KS, respectively. 
The main ﬁnding was that overall, there was no difference in 
HRQoL between the WT groups in different measurement 
points. Nevertheless, those in the NFWT group reached a higher 
level of HRQoL postoperatively and consequently gained 0.033 
QALYs more than the SWT group during the whole observation 
period of almost 700 days. Those in the SWT group had a worse 
pain score at baseline, which reﬂected in an increased use of DSM 
during the waiting period. The weekly costs were almost identi­
cal in both groups at each of the three measurement points. The 
same applies to the mean pain and function scores, which 
reached their highest values 12 months postoperatively. 
In this study, the patients’ HRQoL at baseline was deterio­
rated. In fact, it seems to be worse than in two earlier studies, 
where the mean scores before operation measured by the 15D 
were 0.83 [23] and 0.81 [24] compared to our 0.77 to 0.78. The 
patients had pain and difﬁculties in functioning. Nevertheless, in 
an earlier study among these patients, it was found that they used 
very little health and social services during the WT with no 
statistically signiﬁcant difference between the randomized groups 
[25]. The length of WT alone did not affect HRQoL or pain and 
function scores, which is in line with the ﬁndings of some earlier 
studies [7,8,19]. TKR has been found to be effective [24,26,27], 
and this study also showed a signiﬁcant improvement in HRQoL, 
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Figure 2 The quality-adjusted life-year gain 
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and in pain and function 3 and 12 months postoperatively in 
both randomized groups. 
To our knowledge, no studies have so far been published on 
the effect of WT on the use and costs of DSM after the TKR. 
Earlier prospective studies on the costs and outcomes of the WT 
for TKR have found that waiting more than 6 months was 
associated with higher total costs and deterioration in physical 
function while waiting [28,29]. These cost results are not com­
parable to ours, as they estimated all costs during the waiting 
period. Nunez et al. (2007) ﬁndings on HRQoL and weekly 
medication costs in patients with OA on a waiting list for TKR 
were in line with ours. 
Strengths and Limitations 
The strengths of this study were that the patients awaiting THR 
were prospectively followed from the time of being placed on the 
waiting list to admission—with WTs recorded precisely—and 
further for a year of follow-up postoperatively, providing evi­
dence of the effect of WT on pre- and postoperative health status. 
Further, the patients were randomly assigned to either the SWT 
or NFWT group, the randomization was successfully completed, 
and the groups did not differ from each other at baseline. The 
ﬁndings were based on the simultaneous use of patient-reported 
generic and disease-speciﬁc outcome instruments. The results, 
based on ITT analyses, indicated that there were no statistically 
signiﬁcant differences in health outcomes between the random­
ized groups during the WT. This was also tested with repeated 
measures analyses. The within-subject test indicated that there 
was a signiﬁcant time effect (i.e., the outcomes did change over 
time), but an insigniﬁcant interaction effect (i.e., there was no 
difference between the groups). 
Some limitations pertain to this study. First, the patients who 
refused to participate in the study were older, and second, a total 
of 29 patients in the SWT group waited more than 3 months. The 
reasons were hospitals’ limited capacity to carry out TKR within 
the 3 months WT period or the patient’s unwillingness to have 
TKR within 3 months, or they were too tired to complete the 
questionnaires. Because of these factors, the differences between 
the randomized groups may have been underestimated. Never­
theless, the primary analysis was based on the ITT principle to 
address the question of clinical effectiveness and to avoid the bias 
associated with a nonrandom loss of participants. 
Third, although SF-36 has been widely used in OA area, we 
chose to use the 15D. SF-36 is basically a proﬁle instrument and 
does not thus belong to the category of instruments producing a 
valuation-based single index number. Nevertheless, in 1998, the 
ﬁrst algorithm was published to generate a valuation-based single 
index score, SF-6D score, from the SF-36. Hawthorne et al. [16] 
showed that the 15D performed at least as well as the SF-6D. 
Since a new algorithm has been devised for the SF-6D in 2002 
[30]. Recent research with that algorithm indicates that espe­
cially in the rehabilitation of musculoskeletal disorder, the 15D 
was at least as responsive as the SF-6D [18]. 
Further, we looked at medication cost only, and medication 
information was obtained only from patient self-reports, while 
there was no distinction between self-care and prescription medi­
cation. For temporary medication, we used mean dosages. A 
study is ongoing, where the effect of WTs on the total cost of hip 
and knee replacements is being investigated. 
Conclusion 
In Finland, the so-called treatment guarantee was introduced in 
2005 with a maximum WT of less than 6 months [31]. Since 
then, there has been discussion in health-care policy about the 
optimal and effective WT in elective surgery. When considering 
the optimal timing, information is needed on the effect of WT on 
key parameters. This study showed that the length of the WT, at 
least as realized in practice in this study, did not result in different 
health outcomes in the randomized groups in three cross­
sectional follow-up measurements from baseline to 1 year post­
operatively. Those in the SWT group reached better HRQoL 3 
months earlier than those in the NFWT group, but the latter had 
better HRQoL after the operation and gained more QALYs 
overall during the study period. To be useful for future policy 
work, further research is needed to determine the optimal timing. 
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In many Western countries, long waiting times for elective 
surgery are a concern. Major joint replacement is an example of 
a type of surgery with a high volume of demand and relatively 
long waiting periods for patients. As populations get older, the 
prevalence of slowly progressive diseases, such as osteoarthritis 
(OA) in hip and knee joints, is increasing. Over three-quar ters 
of a million total hip and knee replacement surgeries are done 
in the United States annually (1). Furthermore, according to 
March et al. (1997), the costs of OA have been estimated to 
account for up to 1–2.5 percent of the Gross National Product 
(GNP) in several developed countries (2). In Finland, a total of 
11,104 total joint replacements (TJRs) were perfor med in 2004 
(hip 6,600 and knee 5,905), with the median waiting time of 181 
days for the surgery (hip 153 and knee 209 days). Until 2007, 
the number of TJRs was 17,334 (hip 7,698 and knee 9,636), 
with a median waiting time of 120 and 142 days, respectively 
(3;4). The mean waiting time for elective surgical procedures is 
approximately 3 months in several countries and the maximum 
waiting times can stretch into years. 
An important question is what effect do longer waiting 
times, brought about by lower rates of surgery, have on patient 
welfare. Health status is likely to deteriorate (on average) with 
waiting and welfare will be lower if there is postponement of 
the beneﬁt from surgery (time preference). However, the OECD 
Waiting Times study found surprisingly little evidence, from a 
review of the medical literature, of signiﬁcant deterioration of 
health or worsening of surgical outcomes as a result of waiting 
for elective surgery in those countries where waiting times are up 
to 3 or 6 months, depending on the condition (5). Surgeons seem 
to be good at triage, that is, at re-prioritizing patients whose con-
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ditions become unstable or deteriorate while they wait. Longer 
waiting may be more problematic. A study of patients on the 
waiting list for total hip replacement at one hospital in the United 
Kingdom, using a health status score speciﬁc to hip pathology, 
found evidence of signiﬁcant deterioration and that the deteri­
oration was greater the longer the wait. The median wait, here, 
was approximately 1 year (6). Similarly, a study of patients 
waiting for varicose vein surgery in the United Kingdom found 
“considerable deterioration” in their condition while waiting for 
surgery. In this case, the median wait was 20 months (7). 
It is commonly thought that, due to waiting, there is a de­
terioration in the condition for which treatment is required, a 
loss of health-related quality of life (HRQoL) in the form of 
signiﬁcant pain or disability, as well as an increase in the costs 
of surgery and use of other treatments and healthcare services 
pre- and postoperatively. However, as Siciliani et al. (8) suggest, 
eliminating waiting times altogether would not in fact constitute 
an optimum waiting time from the perspective of the hospital. 
It can be cost-effective to maintain short queues of elective pa­
tients, because the adverse health consequences of short delays 
are small and because there are savings in hospital capacity 
from allowing queues to form (8;9). 
According to earlier studies, patients waiting for TJR have 
a poor quality of life and they have difﬁculties functioning in 
their daily activities (10–15). However, little is known about the 
cost-utility of total joint replacement in relation to waiting time. 
The aim of our prospective, randomized, controlled trial was 
to compare CU of short and longer waiting times for TJR. Many 
observational studies have documented ﬁndings before and af­
ter operations, but such studies do not control for the natural 
course of the disease (4;16–18). According to literature reviews 
by Hoogeboom et al. (1) and ourselves, no prior studies have 
estimated the effect of waiting time on the cost-utility of total 
joint replacement in hip and knee patients using a randomised 
study design. 
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MATERIALS AND METHODS 
Data Collection and Study Design 
Between August 2002 and November 2003, we recruited a total 
of 833 patients from three Finnish hospitals to take part in this 
study. The three hospitals were the Surgical Hospital and Jorvi 
Hospital, which are both part of Helsinki University Central 
Hospital, and Coxa Hospital for Joint Replacement in Tam­
pere. Patients were recruited to take part in the study through 
contact with orthopedic and practice staff during four (at Coxa 
three) recruitment periods (Supplementar y Table 1, which can 
be viewed online at www.journals.cambridge.org/thc2013067). 
Patients’ recruitment is shown in the ﬂow chart (Figure 1) fol­
lowing the requirements of the CONSORT statement. 
The key inclusion criteria were the need for a primar y TJR 
due to OA of the hip or knee joint, as evaluated by the hospital 
surgeon, that the patient was an adult (age >16) and placed on 
the waiting list in a research hospital, and that the patient was 
willing and mentally able to participate in the study. The key 
exclusion criteria were patients with rheumatoid arthritis, frac­
tures, and congenital hemophilia or congenital deformities. 
Randomization 
Once the patients had been placed on the hospital waiting list, 
the study nurse randomly assigned them to one of two groups: 
(i) a short waiting time (SWT) group, with a maximum waiting 
period of 3 months; or (ii) a nonﬁxed waiting time (NfWT) 
group, with surgery perfor med according to the hospital’s rou­
tine procedure and with the waiting period measured from the 
date the patient was added to the waiting list to the date of 
admission for surgery. The number of patients placed on the 
waiting list varied from one month to another, being speciﬁc 
to each hospital. Therefore, we could not estimate in advance 
the number of patients to be placed on the list. The patients 
randomized into the SWT group could only be operated on in 
one of four operating periods (within 2 weeks after each re­
cruitment period) during the year. The arrangement was needed 
because operating rooms for the surgery of SWT patients had to 
be booked in advance before we could recruit the patients. For 
ethical reasons, all patients waiting for total joint replacement 
had to have an equal chance of being recruited to participate in 
the study in either the SWT or the NfWT group. As only half of 
the hospitals’ 1-month surgical capacity could be allocated to 
the SWT group, the number of SWT patients was restricted and 
determined speciﬁcally for each hospital. Therefore, we needed 
to allocate the patients in unequal numbers to either the SWT 
or the NfWT group. 
The researchers generated the random allocation sequence 
using a computer with a random number generator programmed 
with Visual Basic. In each hospital, after being placed on the 
waiting list, we informed the patient about the study and the 
patient provided his or her informed signed consent. The study 
nurse assigned participants to their groups after the decision for 
surgery had been made and informed the patient of the decision. 
A separate randomization procedure was performed within each 
hospital. Surgeons were blind to patient allocation. For ethical 
reasons, double-blinding was not possible. 
The patients used a self-administered questionnaire to 
report their socio-demographic data, comorbidities as diag­
nosed by a medical doctor, HRQoL, disease-speciﬁc medication 
(DSM), ability to function and the degree of pain, and the use 
of health and social services. 
The study was approved by the Helsinki University 
Central Hospital Surgery Ethics Committee (registration np. 
134/E6/02). 
Measurement of HRQoL 
We measured HRQoL using the generic 15D instrument. The 
15D is composed of ﬁfteen dimensions: moving, vision, hear­
ing, breathing, sleeping, eating, speech, eliminating, vitality, 
usual activities, mental function, discomfort and symptoms, de­
pression, distress, and sexual activity. Each dimension has ﬁve 
ordinal levels to choose from. The 15D can be used as a proﬁle 
measure or to give a single index score by means of population­
based preference weights. The index score (15D score) ranges 
from 0 (dead) to 1 (completely healthy) (19). The 15D ques­
tionnaire takes 5–10 minutes to complete and it describes the 
HRQoL of the respondent at present. A difference of >|0.03|
in the 15D score is clinically important in the sense that, on 
average, people can feel the difference (20). We chose to use 
the 15D for three main reasons: (i) it has been used success­
fully in earlier studies dealing with hip and knee replacement 
and thus facilitates a comparison of the presurgery scores in 
these studies; (ii) earlier research has shown that in most of the 
important properties (reliability, content validity, sensitivity in 
terms of discriminator y power and responsiveness to change), 
the 15D instrument compares at least equally with other similar 
instruments that produce a valuation-based single index number 
(21;22); and (iii) recent research has since conﬁrmed that, es­
pecially in the rehabilitation of musculoskeletal disorders, the 
15D instrument was at least as responsive as the SF-6D and 
much more responsive than the EQ-5D (23). 
By using the mean 15D scores from each measurement 
point, and by assuming a linear change in the scores between 
the measurement points, we also estimated the possible gain in 
quality-adjusted life-years (QALY gain) for both groups within 
the obser vation period. To obtain an equally long observation 
period for both randomized groups, we assumed that the ﬁnal 
HRQoL scores in the SWT group would carry forward until 
the mean ﬁnal measurement point in the NfWT group and that 
members of the SWT group would incur no further costs during 
that time. 
Cost Data 
The data on the usage of healthcare and social services were 
based on patients’ self-reports from the waiting time to 1 year 
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postoperatively, which we measured in 3-month periods. We 
obtained the costs for the surgery from the Finnish Hospital 
Discharge Register. We valued the use of healthcare and so­
cial services at Finnish unit costs for the year 2006 (24). The 
total direct costs include the following items: outpatient visits 
(doctor, nurse and chiropodist), the costs of the surgery in­
cluding radiology, laboratory services, hospital days, and reha­
bilitation services. We multiplied the use and costs of regular 
social services due to OA, including meals-on-wheels, home 
help, laundry services, bathing services, and transportation, 
during the waiting time by the number of months spent on 
the waiting list. We carried out all analyses from a Finnish soci­
etal perspective, excluding production losses and value-added 
taxes. 
We used the total costs thus calculated and the QALYs 
gained during the observation period to compare the cost-utility 
of SWT and NfWT separately for hip and knee patients. As 
even the longest observation period was shorter than 2 years, 
no discounting was applied. 
Statistical Analysis 
The sample size estimate was based on the primary outcome 
variable: the 15D score. A subgroup of 177 patients would 
provide an 80 percent power (two-tailed α error 5 percent) of 
detecting clinically important differences L0.03in the mean 
15D score between the randomized groups. We conducted pri­
mary analyses using the intention-to-treat (ITT) principle (24), 
so that we could follow the patients in the groups to which 
they had been randomly allocated. As a secondary analysis 
we looked at patients in the different randomization groups 
with actually shorter and longer waiting times (per protocol 
analysis). 
We compared the characteristics of the randomized groups 
and those who were lost to follow-up at baseline using either the 
independent samples t-test or the chi-squared test, depending on 
whether the variable was on a continuous or a nominal scale. In 
addition, we calculated the mean values for use and the costs of 
health and social services. To assess the degree of uncer tainty 
in the results, we performed a probabilistic sensitivity analysis 
(bootstrapping with 1,000 replicates). The results are given in 
the form of mean incremental costs and effects with their 95 
percent conﬁdence intervals, an incremental cost-effectiveness 
ratio (ICER), a cost-effectiveness plane and a cost-effectiveness 
acceptability curve (CEAC). 
We replaced the missing values on the 15D dimensions, if a 
minimum of 80 percent of the dimensions had been completed, 
using a regression model with the patient’s responses for other 
dimensions, age and gender as explanatory variables (18). Data 
analyses were performed using SPSS versions 14 and 16 for 
Windows. 
RESULTS 
Patient Characteristics 
Of the eligible patients invited to participate in the study, 235 
(160 women) patients with a mean age of 70 years refused 
to participate and were excluded. The most frequently quoted 
reason for refusal was an unwillingness to complete the ques­
tionnaires. Thus, 833 patients, after providing infor med consent, 
were randomly allocated to either the SWT (n = 346) or NfWT 
(n = 487) group (Figure 1). Of the 833 randomized patients, 24 
did not return the questionnaire at baseline, although they had 
signed infor med consent forms and had been randomized. Of 
the remaining 809 patients, 162 were lost to follow-up during 
the waiting time for various reasons and were not included in the 
ﬁnal analyses (Figure 1). Due to missing values, the ﬁnal cost­
utility analyses are based on 550 (66 percent) of the randomized 
patients who completed the questionnaires, with a mean (±SD) 
age of 66 (±9.9; range; from 33 to 89) years, of which 345 (63 
percent) were women and a further 243 (hip n = 130, knee n = 
113) were in the SWT group and 307 (hip n = 149, knee n = 
158) were in the NfWT group (Figure 1). 
The baseline characteristics of the randomized groups were 
similar (Table 1). We have reported the details about the char­
acteristics of these two patient groups in our earlier studies 
(24;25). The mean (±SD) 15D score in the SWT group for hip 
patients was 0.770 (±0.09) and 0.779 (±0.10) in the NfWT 
group; the difference was neither statistically signiﬁcant nor 
clinically important (95 percent conﬁdence interval [CI] for 
a mean difference from −0.036 to 0.026). The mean (±SD) 
15D scores at baseline for knee patients were 0.772 (±0.18) 
and 0.779 (±0.12), respectively (95 percent CI for a mean dif­
ference from −0.004 to 0.030) (Table 1). The percentage of 
patients receiving disease speciﬁc medication (DSM) was more 
than 87 percent in all patients groups. 
Approximately 20 percent (n = 162) of the patients dropped 
out after randomization at any stage of the follow-up. The only 
statistically signiﬁcant differences in the baseline characteristics 
between the dropouts and those, who remained in the study to 
the end of follow-up, were found in the mean age (dropouts 
slightly older) and in the proportion of living alone (among 
dropouts slightly higher) (Table 1). 
Cost-Utility 
The mean waiting time for hip patients was 74 (SD ± 145; 
n = 145) days in the SWT group and 194 (SD ± 175; n = 169) 
days in the NfWT group, and for knee patients 94 (SD ± 81; 
n = 123) days and 239 (SD ± 135; n = 210) days, respectively. 
The 15D score improved after the operation in all four 
groups (Table 2). The mean (±SD) total costs for healthcare 
and social services are reported in Table 3. 
The mean total costs of TJR among hip replacement pa­
tients were EUR 9986 (±3,540) in the SWT group and EUR 10 
472 (±4,686) in the NfWT group, and EUR 9809 (±4,085) and 
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Table 1. Baseline Characteristics in Patients Waiting for Total Joint Replacement and Those Lost to Follow-up 
SWT NFWT Lost
 
Characteristics at baseline n= 268 n= 379 n= 162 p-value‡ p-value†
 
Age, years (mean ± SD) 66 (9.5) 66 (9.7) 68 (9.9) 0.687 0.023∗ 
Females [n, (%)] 185 (65.1) 231 (60.5) 89 (62.2) 0.152 0.538 
Housing [n, (%)] 
Living alone 95 (33.9) 104 (28.1) 59 (41.3) 0.066 0.010∗ 
Basic education [n, (%)] 
Lower level 227 (81.1) 309 (83.3) 119 (83.8) 0.264 0.390 
Comorbidity, yes [n, (%)] 207 (73.9) 270 (72.9) 108 (75.5) 0.406 0.330 
Medication to arthritis, yes [n, (%)] 248 (88.6) 329 (88.7) 124 (86.7) 0.531 0.302 
Medication to comorbidities yes [n, (%)] 215 (76.8) 273 (73.6) 112 (78.3) 0.200 0.232 
Hip 145 (51.1) 169 (47.1) 70 (41.3) 0.126 0.520 
BMIa (mean ± SD) 28.77 (5.68) 28.67 (5.21) 27.66 (7.07) 0.809 0.099 
15D-scoreb (mean ± SD) 0.765 (0.105) 0.774 (0.102) 0.761 (0.120) 0.222 0.360 
∗ p<0,05. 
‡Difference between the randomized groups. 
†Difference between the patients, who remained in the study to the end of follow-up and those lost to follow-up.
 
aBody mass index (kg/m2).
 
b15D-score (scale 0 = worst, 1 = best).
 
Table 2. Mean 15D Scores in the Randomized Groups of Hip and Knee Patients 
Measurement point Hip SWT NfWT 95% CI for mean difference Knee SWT NfWT 95% CI for mean difference 
At baseline (±SD) 0.770 (0.09) 0.779 (0.10) −0.036 to 0.026 0.772 (0.18) 0.779 (0.12) −0.004 to 0.030
 
At admission (±SD) 0.772 (0.09) 0.771(0.10) −0.023 to 0.021 0.778 (0.11) 0.786 (0.13) −0.008 to 0.014
 
Three months pop (±SD) 0.945 (1.06) 0.854(0.11) −0.277 to 0.094 0.811 (0.12) 0.842 (0.11) 0.033 to 0.058∗
 
One year pop (±SD) 0.854(0.12) 0.904 (0.50) −0.033 to 0.133 0.823 (0.14) 0.852 (0.10) 0.019 to 0.035∗
 
∗ p<0.01.
 
Table 3. Mean Use and Costs of Healthcare and Social Services during the Waiting Time between the Randomized Groups, in Hip and Knee Patients
 
Mean number Mean costs in hip Mean coosts in knee 
in hip patients Mean number in knee patients patients (€) patients (€) 
SWT NfWT SWT NfWT 
Items of resource use n= 130 n= 149 n= 113 n= 158 SWT NfWT SWT NfWT 
Outpatients’ visits 1.9 1.4 1.5 1.2 232 152 188 129 
Hospital days 0.2 0.4 0.9 0.4 118 266 377 247 
Healthcare service (at home) 0.3 0.1 0.1 0.1 8 4 4 1 
Rehabilitation 1.0 0.2 0.5 0.3 61 16 21 14 
Homecare service 0.6 0.6 1.3 1.2 21 21 38 33 
aSum of different types of hospital outpatients’ units (University hospital, central hospital, district hospital, health care centre, private hospital, occupational health care unit). 
bRegular homecare services due to osteoarthritis. 
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EUR 9801 (±3,116) among knee replacement patients, respec­
tively. During the equally long follow-up period, the SWT hip 
patients experienced, on average, 1.341 QALYs and the NfWT 
patients 1.327 QALYs. Correspondingly, the SWT knee pa­
tients experienced, on average, 1.453 QALYs and the NfWT 
patients 1.467 QALYs (Supplementar y Table 2, which can 
be viewed online at www.journals.cambridge.org/thc2013068). 
Point estimates thus suggest a strong dominance for SWT 
among hip patients but for NfWT among knee patients (Sup­
plementar y Figures 1, 2, which can be viewed online at 
www.journals.cambridge.org/thc2013069 and www.journals. 
cambridge.org/thc2013070). On the basis of probabilistic sen­
sitivity analysis in hip patients, the 95 percent CI for the mean 
difference in QALYs was from −0.048 to 0.076 and in costs 
from −1453€ to 464€. In knee patients, the 95 percent CI for 
the mean difference in QALYs was from −0.095 to 0.063 and in 
costs from −913€ to 955€. If the willingness to pay for a QALY 
is EUR 20,000, the probability of SWT being cost-effective for 
hip patients is approximately 85 percent and approximately 40 
percent for knee patients (Supplementar y Figure 3, which can 
be viewed online at www.journals.cambridge.org/thc2013071). 
In the secondary per protocol analysis the mean total costs 
among hip patients were EUR 10,302 (±3788) in the SWT 
group and EUR 10,402 (± 4854) in the NfWT group, and EUR 
9,374 (±3259) and EUR 9904 (±3115) among knee patients, 
respectively. During the equally long follow-up period, the SWT 
hip patients experienced, on average, 1.3536 QALYs and the 
NfWT patients 1.3879 QALYs. Correspondingly, the SWT knee 
patients experienced, on average, 1.4428 QALYs and the NfWT 
patients 1.5022 QALYs. Point estimates thus suggest an ICER 
of EUR 3000 for NfWT among hip patients and of EUR 9058 
among knee patients. However, there is a lot of variance around 
the point estimates and the differences in costs and QALYs 
between the per protocol groups were not statistically signiﬁcant 
neither in hip nor knee patients. 
DISCUSSION 
Scientiﬁc evidence on the relationship between waiting time and 
outcomes for TJR is inconsistent. The absence of randomized 
trials has prevented an assessment of whether longer waiting is 
somehow related to HRQoL outcomes and costs. The present 
study compared the cost-utility of short and longer waiting times 
for TJR. To our knowledge, this study is the ﬁrst one in which 
patients were randomly allocated to short and nonﬁxed wait­
ing time groups when placed on the waiting list and followed 
according to the ITT principle. 
The main ﬁnding of this study was that hip patients in the 
SWT group gained, on average, more QALYs at lower costs than 
patients in the NfWT group, suggesting a strong dominance for 
the SWT group. In knee patients the situation was the opposite. 
However, there is a high degree of uncertainty surrounding these 
results based on point estimates, and probabilistic sensitivity 
analyses indicated that if the willingness to pay for a QALY 
is EUR 20 000, then the probability of a SWT being cost­
effective in hip patients is approximately 85 percent and only 
approximately 40 percent in knee patients. 
It is to be noted although that our ﬁndings may not be fully 
transferable to other countries. Even by using the same HRQoL 
instrument and valuation algorithm, the HRQoL results may 
not be similar due to different indications of treatment. Trans­
ferability of costs is shadowed by differences across countries 
e.g. in treatment practices and unit costs. 
Strengths and Limitations 
There are some limitations to this study. First, a total of seventy­
four patients in the SWT group waited for more than 3 months. 
The main reasons for this were the hospitals’ limited capacity 
to carry out TJR within the 3-month waiting time period or 
the patients’ unwillingness to be operated on within 3 months. 
Due to these factors, the differences between the randomized 
groups may have been underestimated and there might also be 
some bias in the use of health and social services. However, the 
primary analysis was based on the ITT principle to address the 
question of clinical effectiveness and to avoid the bias associated 
with a nonrandom loss of participants. 
The per protocol analysis gave rise to further uncertainty 
over whether there is any real difference between the waiting 
time groups in cost-utility in either procedure. The point esti­
mates suggested an ICER of EUR 3000 for NfWT among hip 
patients and of EUR 9058 among knee patients, but the differ­
ences in costs and QALYs between the per protocol groups were 
not statistically signiﬁcant neither in hip nor knee patients. 
Second, deﬁning and measuring the waiting time for surgery 
is not a simple matter. What is the real starting point for the 
waiting period? According to Siciliani and Hurst (2003), one 
observable starting point is the time when a patient is ﬁrst 
refer red by a general practitioner to a hospital to be assessed 
for surgery. In the present study, the waiting time began when 
the practitioner ﬁrst made the decision for surgery, even though 
patients may have already been waiting for an unknown amount 
of time before this decision. This might affect patients’ baseline 
quality of life, which was poor (5). 
Third, also establishing comparable QALYs and costs be­
tween the SWT and NfWT group is not without weaknesses, as 
the ﬁnal measurements of HRQoL and costs in both groups did 
not take place equidistantly in time from the baseline. With our 
solution, the mean follow-up time is the same in both groups. 
However, we do not know exactly, how the HRQoL and costs in 
the SWT group developed during the time from the last measure­
ment in that group to the ﬁnal measurement in the NfWT group. 
The HRQoL may have deteriorated slightly due to ageing, but 
as the mean time difference between the last measurements in 
the groups was only 4–8 months, the change would probably be 
negligible; therefore, our assumption of no change may be jus­
tiﬁed. On the other hand, had the SWT group incurred further 
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costs contrar y to our assumption, its total cost would have 
been underestimated. As these changes would probably been 
marginal, they may have not affected our conclusions. 
Another possible weakness is that approximately one-third 
of patients dropped out during the follow-up. However, apart 
from being slightly older and living slightly more frequently 
alone, the dropouts did not deviate in a statistically signiﬁcant 
manner in their baseline characteristics from those, who re­
mained in the study to the end of follow-up. Thus overall, the 
dropout may not bias our results signiﬁcantly. 
Finally, the costs of medication were not included in the ﬁnal 
analyses; the costs have been reported in our earlier studies and 
the ﬁndings were that the cost trends were highest during the 
waiting time and lowest after the operation (15;26;27). 
The strengths of this study are that the patients awaiting TJR 
were prospectively followed from the time of ﬁrst being placed 
on the waiting list to admission—with waiting times recorded 
precisely—and further for a year postoperatively, providing ev­
idence of the effect of waiting time on pre- and postoperative 
health status. Furthermore, the patients were randomly assigned 
to the SWT and NfWT groups; the randomization was success­
fully completed and the groups did not differ from each other 
at baseline. 
CONCLUSION 
According to the present study, there does not seem to be a sig­
niﬁcant difference in the cost-utility of short and longer waiting 
times for TJR, at least given the waiting time difference between 
our study groups. 
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